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ISOLATED SYSTOLIC HYPERTENSION 
 
INTRODUCTION 
 
Until the mid 20th century, clinicians' concern was directed mainly to 
the systolic component of blood pressure1. Later, however, when systolic 
blood pressure was found to be elevated with advancing age and decreased 
compliance of the arterial wall,1,2 it began to be considered an inevitable 
consequence of aging1-3. However, there is now compelling evidence from 
cross sectional, longitudinal, and randomized controlled trials that show that 
isolated systolic hypertension confers a substantial cardiovascular risk.4,5 
Despite this, it remains under diagnosed and largely untreated.6 The roots of 
this lie in a century of over reliance on the importance of diastolic pressure 
and largely unjustified concerns about the potential adverse consequences of 
treating systolic pressure.  
After the mercury sphygmomanometer was introduced, convention 
dictated that diastolic pressure was a better determinant of cardiovascular 
risk than systolic pressure. Systolic pressure was thought to vary 
considerably throughout the day, and a high pressure was believed to reflect 
a “strong” left ventricle. This view was perpetuated by the reliance of life 
assurance companies on diastolic pressure and the use of diastolic pressure 
in the early studies of lowering blood pressure. The use of diastolic pressure 
was further supported by the discovery that essential hypertension is 
characterized by increased peripheral vascular resistance and therefore 
raised mean arterial pressure, which more closely correlates with diastolic 
than systolic pressure. Evidence that systolic pressure is equally, if not more, 
important than diastolic, particularly in people over 50, was largely ignored.  
Although the use of diastolic pressure for risk prediction may be 
reasonably effective for younger people and people with essential 
hypertension, data from cohort and intervention studies indicate that it is 
inappropriate for the over 50s, particularly those with isolated systolic 
hypertension7. Nevertheless, isolated systolic hypertension is not a benign 
condition. The latest data from the Framingham study, showing, at least in 
the over 50s, that arterial stiffness is a key determinant of cardiovascular 
risk.8 Despite continued reluctance to accept isolated systolic hypertension as 
a discrete pathological entity, the benefits of treatment are established.4,5 The 
relative risk reduction of cardiovascular events in elderly people with 
isolated systolic hypertension, reported in the latest Cochrane review, is 
similar to that in younger people.9 However, as elderly people are at much 
higher absolute risk of such events, they stand to benefit more from 
treatment than younger people. Moreover, elderly people tolerate 
antihypertensive drugs with few side effects.9 Yet patients with isolated 
systolic hypertension remain under-recognized and undertreated.6  
The latest World Health Organization and Inter- national Society of 
Hypertension guidelines for the management of hypertension emphasize the 
importance of arterial stiffness and pulse pressure as predictors of 
cardiovascular risk and call for further investigation of the prognostic 
relevance of other indices of arterial stiffness.10 The enemy today is no 
longer arterial pressure taken in isolation, but a collection of factors, of 
which age and doctors' conservatism are among the most important.11 It is 
high time that we recognize Isolated Systolic Hypertension as an important 
clinical condition and update our practicing guidelines accordingly. 
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AIM OF THE STUDY 
 
 
 
 
 
 
 
 To study the clinical profile of Hypertensives with Isolated 
Systolic Hypertension in terms of Symptomatology, History, 
Clinical features and Laboratory data. 
 
 To study the determinants of Isolated Systolic Hypertension. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
EPIDEMIOLOGY AND RISK 
 
Hypertension is present in more than half of all persons over 60 years 
of age, regardless of race10. The majority of hypertensive patients in this age-
group have ISH11,12. Isolated systolic hypertension(ISH) has been identified 
as an entity since long13. About 20% of the elderly suffer from ISH14. ISH 
leads to three fold risks of cardiovascular accidents, and 2.2 fold rise in the 
risk of myocardial infarction14. Recent evidence that treating ISH leads to a 
lowering of cardiovascular morbidity and mortality has aroused keen interest 
in this entity13. There is a paucity of reliable estimates of burden of diseases 
and distribution of cardiovascular risk factors. Disaggregated data about the 
burden of disease and risk factors in the community is required for the 
prevention of cardiovascular disease. 
Both the SBP and DBP increase with age in men and women until the 
early 50s. Between the ages of 54 and 59 years, DBP plateaus and there after 
falls modestly for the remainder of life. The prevalence of  elevated 
DBP(that is, 90 mm Hg or more), therefore, increases until the mid-
50s.Elevated SBP(for example,140 mm Hg or more) is infrequent before the 
age of 50, begins to raise in prevalence about age 55, and continuous to 
increase well beyond the age of 80. Further, the national health and nutrition 
examination survey (NHANES)-III data demonstrate that for Americans 
between the ages of 55 and 74. Women have slightly higher prevalence of 
elevated SBP than men and African-Americans have a higher prevalence 
than Caucasians. African-American females as a race-sex group have the 
highest prevalence at 11.3%. 
Since 1993 in the United States, systolic BP has been given equal 
weight to diastolic BP in the diagnostic scheme for hypertension. Elevated 
systolic BPs have been identified as a major public health problem, for 
several reasons15. The lifetime risk in Framingham for 55 or 65 year old men 
or women to develop hypertension is 90 percent16. Most importantly, for 
people over age 50 or 60 years, systolic BP is a much better predictor of  
TOD and future CV and renal events than diastolic BP15,17 . Overall, each 20 
mmHg increase in systolic BP doubles cardiovascular risk18. 
The number of elderly among the populations of the United States and 
many other countries is rising rapidly. At the beginning of the 20th century, 
only 4% of the US population was older than 65 years of age. By 2040, the 
comparable figure is estimated to be 21%. Clearly, therefore, ISH will be an 
important issue for practitioners in the years to come.   
HISTORICAL REVIEW 
 
 Diastolic Blood Pressure (DBP), as opposed to Systolic Blood 
Pressure (SBP) or the combination, became the focus of cardiovascular risk 
assessment relatively early in the 20th century and of hypertensive treatment 
trials in 1970s. Clinical trials focusing on diastolic hypertension showed that 
associated deaths from all causes and strokes could be reduced by vigorous 
treatment. 
 A renewed interest in SBP, its elevation, and associated risks was 
generated first by an analysis of the Build and Blood Pressure study in 1959. 
That and other studies demonstrated unequivocally that an elevation of SBP 
was associated with an increase of morbidity and mortality, especially 
among older people. Some analyses were done with adjustments made for 
other risk factors. As Fisher points out, in every study where the effect of 
elevations of DBP and SBP have been compared, elevations of SBP have 
consistently shown greater associated risk for stroke Coronary Heart 
Diseases (CHD), and mortality from all causes. Further, the data showed that 
an elevation of SBP in the presence of normal DBP (that is, Isolated Systolic 
Hypertension) [ISH] was associated with an increased risk of stroke, 
cardiovascular disease, and mortality from any cause. Systolic Hypertension 
in the Elderly Program (SHEP) was the first clinical trial of antihypertensive 
therapy to focus on SBP and specifically ISH.  
SHEP Trial 
SHEP19 is a multicenter, randomized, double-blind, placebo-
controlled trial of treatment for ISH in 4736 persons aged >/=60 years in a 
community based ambulatory population in tertiary care centers. In the 
Systolic Hypertension in the Elderly Program (SHEP), treatment with the 
diuretic agent chlorthalidone for an average of 4.5 years in patients with 
systolic blood pressure of 160 mm Hg or greater and diastolic pressure 
below 90 mm Hg resulted in impressive reductions in the incidence of stroke 
(–36%), coronary heart disease (–27%), and congestive heart failure (–55%), 
as compared with placebo20. 
Syst-Eur Trial 
The Syst-Eur trial21 was a randomized, double-blind, placebo-
controlled trial in elderly patients with ISH aged >/=60. ISH in Syst-Eur was 
defined as an SBP of 160-219 mm Hg and a DBP of <95 mm Hg. The 
patients received the dihydropyridine nitrendipine or a placebo (n=2398 vs. 
2297). Nitrendipine was supplemented with enalapril, and further with 
hydrochlorothiazide, if needed, to achieve blood pressure control. The study 
was prematurely stopped after the second interim analysis showed a 
significant decrease in occurrence of strokes in the active treatment group.  
In the European Trial in Systolic Hypertension and in the Systolic 
Hypertension in China Trial, treatment was associated with decreases in the 
incidence of stroke (–42 and –38%, respectively), coronary heart disease (–
30 and –6%), and congestive heart failure (–29 and –58%).22   
Syst-China Trial 
The Syst-China trial23 was a study of 2394 Chinese patients aged 
>/=60 with ISH in which an alternative assignments approach of titrated 
drug therapy or placebo was used. As in Syst-Eur, ISH in Syst-China was 
defined as an SBP of 160-219 mm Hg with a DBP of <95 mm Hg. The 
blood pressure goal in the active treatment group was to lower the SBP to 
<150 mm Hg and to achieve a change in sitting SBP of >/=20 mm Hg. 
Nitrendipine was used as initial therapy in the active treatment group 
and was supplemented, if needed, with captopril, hydrochlorothiazide, or 
both. The incidences of stroke and other cardiovascular diseases were the 
main outcome measures. The blinded end point committee reviewed and 
validated all end points, which were defined as in Syst-Eur. 
A meta-analysis of eight trials involving several drug regimens in 
patients 60 years of age or older with systolic pressure of 160 mm Hg or 
greater and diastolic pressure below 95 mm Hg showed that antihypertensive 
therapy administered for an average of 3.8 years reduced total mortality by 
13% and mortality due to cardiovascular disease by 18%. In addition, all 
complications of cardiovascular disease were reduced by 26%, stroke by 
30%, and coronary heart disease events by 23%24. 
PATHOPHYSIOLOGY OF ESSENTIAL HYPERTENSION 
 
       Systemic Hypertension is a disorder of BP regulation from multitude 
causes25. Control of BP involves complex interactions among the kidneys, 
the central nervous system (CNS) and peripheral nervous system (PNS), and 
the vascular endothelium throughout the body as well as a variety of the 
other organs, such as the adrenal and pituitary glands. The heart is the organ 
that responds to many of the changes mediated by these systems. It also 
secretes hormones locally and systemically that help regulate BP. In people 
genetically predisposed to develop hypertension, an imbalance occurs 
among the various systems that modulate BP. 
 The sympathetic nervous system (SNS), the renin angiotensin-
aldosterone (RAA) system, vasopressin (VP), nitric oxide (NO), and a host 
of vasoactive peptides, including endothelin, adrenomedullin, and others 
produced by heart and many different cells (endothelial and vascular smooth 
cells), modulate the responses of the systems and help maintain BP over a 
range commensurate with optimum physical and mental activity.  
 
PATHOPHYSIOLOGY OF ISOLATED SYSTOLIC 
HYPERTENSION 
 
 Factors that may play a role in the high prevalence of ISH include 
increased body fat, sedentary lifestyle, and increased sodium intake. A 
decreased distensibility of the aorta and other large arteries, or the loss of the 
Windkessel-function., is known to be the main pathophysiologic feature of 
ISH. Interestingly, systolic blood pressure itself is one of the determinants of 
aortic distensibility. This may lead to the hypothesis of a vicious circle of 
high systolic blood pressure decreasing aortic distensibility which in itself 
increases systolic blood pressure: systolic hypertension begets systolic 
hypertension. 
Increased cardiac output may play a role in ISH. In addition, elderly 
hypertensive patients tend to have relatively low plasma volume and 
relatively low levels of rennin and aldosterone. Renal excretion of salt tends 
to be decreased in these patients, and this probably accounts for relatively 
greater salt sensitivity compared with their younger counterparts. Decreased 
calcium levels resulting from increased calciuria and poor dietary intake 
may also increase peripheral resistance, leading to hypertension. 
MECHANISMS OF VASCULAR STIFFNESS 
 
Vascular stiffening develops from a complex interaction between 
stable and dynamic changes involving structural and cellular elements of the 
vessel wall. These vascular alterations are influenced by hemodynamic 
forces26 as well as by "extrinsic factors" such as hormones, salt, and glucose 
regulation. Stiffness is not uniformly disseminated throughout the vascular 
tree but is often patchy,27  occurring in central and conduit vessels while 
sparing the more peripheral arteries.28  
 
STRUCTURAL COMPONENTS OF ARTERIAL 
STIFFENING 
 
 The stability, resilience, and compliance of the vascular wall are 
dependent on the relative contribution of its 2 prominent scaffolding 
proteins: collagen and elastin. The relative content of these molecules is 
normally held stable by a slow, but dynamic, process of production and 
degradation. Dysregulation of this balance, mainly by stimulation of an 
inflammatory milieu, leads to overproduction of abnormal collagen and 
diminished quantities of normal elastin, which contribute to vascular 
stiffness.29 Increased luminal pressure, or hypertension, also stimulates 
excessive collagen production.30 On gross pathologic vascular specimens, 
these molecular changes manifest as a doubling to tripling of intima-medial 
thickness between ages 20 to 90,31  as well as a hypertrophied vascular 
smooth muscle layer.32  
Histological examination of the intima of stiffened vessels reveals 
abnormal and disarrayed endothelial cells, increased collagen, frayed and 
broken elastin molecules, infiltration of vascular smooth muscle cells, 
macrophages and mononuclear cells, and increased matrix 
metalloproteinases, transforming growth factor (TGF)-ß, intracellular cell 
adhesion molecules, and cytokines.33 In addition to vessel wall thickening, 
aging is associated with a gradual increase in central artery lumen diameter 
(9% per decade from 20 to 60 years in the ascending aorta),34 although some 
recent studies have suggested this does not occur.  
CELLULAR ROLE IN VASCULAR STIFFENING 
 
  
In addition to structural changes, arterial stiffness is strongly affected 
by endothelial cell signaling and vascular smooth muscle cell (VSMC) tone. 
VSMC tone can be modified by mechanostimulation, itself, in part because 
of cell stretch and changes in calcium signaling, and by paracrine mediators 
such as angiotensin II,35 endothelin, oxidant stress, and nitric oxide. 
Endothelial dysfunction is evidenced clinically by an impaired vasodilatory 
response to acetylcholine.36 This stems, in part, from an imbalance between 
nitric oxide and endothelial-derived hyperpolarizing factor and constricting 
hormones, and oxygenases (eg, cyclooxygenase, NADPH, and xanthine 
oxidase).37 Nitric oxide expression may itself be reduced, and increased 
expression of a natural nitric oxide synthase (NOS) inhibitor, asymmetrical 
dimethylarginine, has been linked to vascular stiffening. Bioavailability of 
nitric oxide is also reduced by activation of reactive oxygen species caused 
by stress, hormones, and likely AGEs.38 The formation of peroxynitrite and 
other highly reactive species results in abnormal vascular tone.  
NEUROENDOCRINE SIGNALING AND SALT 
 
 
 Many hormones are known to modulate vascular stiffness. 
Angiotensin II (AII) stimulates collagen formation, triggers matrix 
remodeling and vascular hypertrophy, depresses nitric oxide-dependent 
signaling, increases oxidant stress, and reduces elastin synthesis.35 In 
addition, AII stimulates cytokines and growth factors in the matrix that 
contribute to an increased inflammatory response.  Many of these changes 
are transduced by AII-stimulated NADPH oxidase and NOS uncoupling.39 
Aldosterone (ALDO) synthesis is primarily controlled by the action of AII 
on the angiotensin type I receptor, and also promotes vascular stiffness and 
hypertension by stimulating VSMC hypertrophy, fibrosis, and fibronectin.40  
The action of ALDO is closely tied to endothelin-1; infusion of ALDO 
increases endothelin-1 production, which has vasoconstrictive and “fibrotic” 
effects on the vasculature itself.  
 
GLUCOSE, INSULIN, AND VASCULAR STIFFENING 
 
Hyperinsulinemia itself has proliferative effects, because insulin 
resistance impairs PI3-kinase–dependent signaling responsible for the acute 
metabolic effects of insulin, yet activity of growth-promoting mitogen 
activated kinase pathways remains relatively preserved.41 Impaired glucose 
tolerance also enhances nonenzymatic glycation of proteins with covalent 
cross-linking of collagen (AGEs) and alters the mechanical properties of 
interstitial tissue of the arterial wall.42 Stiffness is further increased by 
endothelial dysfunction caused by high LDLs, free fatty acids, endothelin-l, 
inadequate vasodilatory effects of insulin, or decreased levels of adiponectin 
and natriuretic peptides.43 Importantly, increased arterial stiffness in the 
metabolic syndrome is not the consequence of fully established diabetes, but 
rather caused by subtle hormonal and metabolic abnormalities present from 
the very beginning of an insulin-resistant state.  
GENETICS OF VASCULAR STIFFENING 
 
Given the involvement of numerous proteins and hormones in 
vascular stiffening, it is perhaps not surprising that genetic polymorphisms 
have been identified that are associated with increased arterial stiffening. In a 
recent genome-wide scan of the Framingham Heart Study population, 
DeStefano et al report that having chronically increased arterial pulse 
pressure has moderate inheritability (0.51 to 0.52). There appears to be 
minimal overlap between linkage peaks of pulse pressure (PP) versus 
systolic or diastolic pressure,44 suggesting that genes contributing to PP 
variability are separate. Several highly suggestive regions have been 
identified, some in concordance with genome scans in different cohorts, such 
as 122 cM region of 15 chromosome, 164 cM region of 8 chromosome (in 
proximity of ALDO synthase gene), and 70 cM region of 7 chromosome.45 
 
 
VASCULAR STIFFENING PATHOBIOLOGY 
 
Vascular stiffening results in widening of the arterial pulse pressure, 
which can profoundly influence blood vessel and heart biology. In arteries, 
the impact is primarily related to changes to mechanical vascular stimulation 
caused by increased pulsatile shear and pressure.46 Local regions near 
bifurcations have more turbulent flow and experience a higher amplitude of 
oscillatory shear stress with elevated stress, magnifying endothelial 
dysfunction and vascular disease.47 In compliant arteries, increased pulsatile 
perfusion can augment vasodilation, a change linked to enhanced nitric oxide 
production as well as activation of calcium-sensitive K+ channels linked to 
endothelial-derived hyperpolarizing factor.  This is further amplified when 
PP is enhanced in vascular beds dilated by local stimulation of ATP-
sensitive K+ channels,48 a common mechanism regulating regional flow in 
the coronary arteries and peripheral vasculature. However, this augmentation 
of flow by pulse perfusion may require normal vascular distensibility, 
because reduction of wall compliance appears to block key signaling 
involved with this response.  
 
 
CLINICAL IMPLICATIONS OF VASCULAR STIFFENING 
 
Isolated systolic hypertension (defined as systolic blood pressure >140 
and diastolic blood pressure <90 mm Hg) and elevated pulse pressure 
(PP=systolic blood pressure–diastolic blood pressure) are 2 clinical 
manifestations of decreased vascular distensibility.49 The prevalence of 
hypertension increases with age such that >60% of people older than age 65 
years are hypertensive with systolic blood pressure >140 mm Hg and/or a 
diastolic blood pressure >90 mm Hg; older blacks have a higher prevalence 
of hypertension than do whites in all age groups.50 However, unlike younger 
hypertensive subjects in whom systolic blood pressure, diastolic blood 
pressure, and MAP are all risks for cardiovascular events,51 Isolated Systolic 
Hypertension and elevated PP pose more significant risks for strokes, 
myocardial infarctions, heart failure, and overall mortality in older adults.52  
This difference in risk implies a different pathophysiological mechanism for 
hypertension in younger versus older individuals and perhaps a different 
therapeutic approach.53 “In fact, it is reported that every 2-mm Hg increase 
in systolic blood pressure increases the risk of fatal stroke by 7% and fatal 
coronary heart disease event by 5%.”54  
 
DIAGNOSIS OF HYPERTENSION 
 Objective measurements were made easier by the instruments of 
Janeway and Korotkoff, who characterized the sounds heard when the 
stethoscope was placed over the compressed artery in 1905. The terminology 
introduced by Korotkoff is still used today: systolic BP is recognized when 
clear and repetitive tapping sounds are heard; diastolic BP is recorded when 
the sounds disappear. An exception is recognized among patients who have 
audible sounds even down to zero millimeters of mercury; the “muffling” of 
the sounds (Korotkoff phase IV) is then recorded before the zero55. 
TECHNIQUES OF MEASURING BLOOD PRESSURE 
 To accurately measure BP, the deflation rate of the column of mercury 
should be 2 to 3 mm Hg/s. the lower rate of deflation should be used in for 
persons with heart rate less than 72 beats per minute(bpm); the more rapid 
deflation is appropriate only for those with resting tachycardia. If the 
precision of measurement is to be atleast 2mm Hg, the observer should have 
the opportunity to hear atleast one Korotkoffs sound at each 2mm Hg 
gradation of the mercury column. Thus, the proper deflation rate depends on 
the heart rate of the subject and is unlikely to be more than 3mm Hg/s if a 
precise BP measurement is desired.  
 It is usual for a single BP measurement to be an accurate indicator of 
future CV risk; multiple measurements made on different occasions are 
more likely to be helpful in deciding whether a particular person ought to 
have his or her BP lowered. 
HOME BLOOD PRESSURE MEASUREMENTS 
 Home BP readings are typically lower (by an average of about 12/7 
mm Hg) than measurements taken in the traditional medical environment, 
even in normotensive subjects56. Home readings tend to be better correlated 
with both the extent of TOD and the risk of future mortality than are 
readings taken in the physician’s office57. Home readings can be helpful in 
evaluating symptoms suggestive of hypotension, especially if the symptoms 
are intermittent or infrequent. Home BP readings should be interpreted 
cautiously, carefully and conservatively58. There are no long-term clinical 
trials that based all treatment decisions solely on home readings, but several 
reports show benefit from supplementing office BP measurements with 
home readings59. 
AMBULATORY BLOOD PRESSURE MONITORING(ABPM) 
 ABPM makes it possible to measure BP routinely during sleep and 
has reawakened interest in the circadian variation of HR and BP. Most 
normotensives and perhaps 80 percent of hypertensives have at least a 10 
percent drop in BP during sleep compared with the daytime average. 
Although there may be some important demographic confounders (blacks 
and the elderly have less prominent “dips”60), several prospective studies 
have shown an increased risk of CV events (and proteineria in type 1 
diabetics61) among those with a nocturnal “nondipping” BP or pulse 
pattern62. However, there is concern, based on several Japanese studies, that 
elderly persons with more than a 20 percent difference between nighttime 
and daytime average BPs (“excessive dippers”) may suffer unrecognized 
ischemia in “watershed areas” (of the brain and other organs) during sleep of 
their BP declines below the autoregulatory threshold63-65. 
 During the last 20 years, research has demonstrated an important 
correlation between ABPM readings and the prevalence and extent of TOD 
in hypertensives. Compared with “casual” BP measurements (obtained in the 
health care provider’s office), ABPM measurements clearly are a better 
predictor of LVH, cardiac function, and overall scores summing optic, 
carotid, cardiac, renal, and peripheral vascular damage resulting from 
elevated BP. Ambulatory BP monitoring may also be useful  in identifying 
“white coat normotensives”. In the first published study of outcomes in 
central Italy, ABPM was the best predictor of future CV events; “nondipper 
hypertensives” had approximately three times the risk of hypertensives 
whose BP was ≥10 percent lower at night compared to daytime (“dippers”). 
Continued follow-up and refinements in these analyses come to the same 
conclusions. 
WHITE COAT HYPERTENSION 
 The name white coat hypertension has been given to the situation in 
which BP measurements outside the health care setting are considerably 
lower than those in it, even though the “White Coat” itself is unlikely to be 
the only factor that increases BP. Even in the largest and longest experience, 
the risk of future CV events did not differ between white coat and sustained 
hypertensives when both were treated with antihypertensive medications66. 
PSEUDO HYPERTENSION 
 
Osler’s manoeuver, the sign of cuff artifact due to arterial stiffness 
described by Messerli et al67 and so named because Osler, in his 1892 text, 
indicated that he mistrusted the BP reading in patients with stiff arteries, in 
whom the radial artery was still palpable even though the cuff had been 
inflated above the systolic pressure. Messerli et al called patients with that 
finding ‘Osler manoeuver positive’ (OM+), and found discrepancies between 
the cuff and intra-arterial diastolic pressure in such patients, ranging from 10 
to 54 mm Hg. In the cohort of patients being screened for SHEP (the 
Systolic Hypertension in the Elderly Program) studied by Wright and 
Looney, 243 of 3387 patients (7.2%) were OM+. They suggest that Osler’s 
manoeuver Osler manoeuver could be used to identify patients with 
pseudohypertension. 
Pseudohypertension is a problem in some elderly patients with stiff 
arteries. Its prevalence is still unclear; the problem occurs in approximately 
half of elderly patients with diastolic pressure > 100 mm Hg but no end-
organ disease. Belmin et al68 found that 5.8% of elderly geriatric in-patients 
were OM+ , and Wright and Looney69 found that 7.2% of patients screened 
for SHEP at their centre were OM+ ; however, not all those patients will have 
pseudohypertension. 
Osler’s manoeuver may be used to raise clinical suspicion of a large 
cuff artifact, but further evaluation is required to establish the true BP level; 
new approaches to sorting this out are ultrasound determination of arterial 
closing pressure, and BP measurement with a finger cuff. The diagnosis 
should be suspected in elderly patients with resistant high diastolic pressures 
and no end-organ disease, who complain of light-headedness when the BP is 
treated to levels that do not explain the symptoms. 
EVALUATION OF THE HYPERTENSIVE PATIENT 
 Six key issues must be addressed during the initial office evaluation of 
a person with elevated BP readings: 
• Documenting an accurate diagnosis of hypertension. 
• Defining the presence or absence of TOD related to hypertension. 
• Screening for other CV risk factors that often accompany 
hypertension. 
• Stratifying risk for CVD. 
• Assessing whether the person is likely to have an identifiable cause of 
hypertension (secondary hypertension) and should have further 
diagnostic testing to confirm or exclude the diagnosis. 
• Obtaining data that may be helpful in the initial choice and subsequent 
choice of therapy. 
ROUTINE EVALUATION IN ALL HYPERTENSIVE 
PATIENTS 
 The recommendations of JNC 7 and other national and international 
expert panels limit the number of initial tests and the expense related to the 
for the routine evaluation of hypertensive patients70. Those that are used in 
assessing the presence or absence of TOD include physical examination, 
blood urea nitrogen (BUN)/creatinine, electrolytes, urinalysis, and an 
electrocardiogram (ECG). Assessing the number of CV risk factors can be 
accomplished with the medical history, chemistry panel (glucose, lipid 
profile) and urinalysis.  
BLOOD PRESSURE CLASSIFICATION IN ADULTS (JNC-7) 
 
By Joint National Committee on Prevention, Detection, Evaluation 
and Treatment of High Blood Pressure 
 
 
BP Classification 
 
SBP 
mm Hg 
 
DBP 
mm Hg 
 
     Normal 
 
     Pre hypertension 
 
  Stage I hypertension 
 
   Stage II hypertension 
 
 
<120 
 
120-139 
 
140-159 
 
≥160 
 
<80 
 
80-89 
 
90-99 
 
≥100 
 
EVALUATION IN ISOLATED SYSTOLIC 
HYPERTENSION 
 
The initial evaluation of the patient with systolic hypertension should 
include an assessment for the presence of other cardiovascular risk factors, 
end-organ damage, concomitant diseases affecting prognosis and treatment, 
identifiable causes of hypertension (e.g., hyperthyroidism) and potentially 
contributing lifestyle factors (diet and exercise).70 
MANAGEMENT 
 
The therapeutic approach and goals for isolated systolic hypertension 
are similar to those recommended for most other types of hypertension. The 
recommended target level of blood pressure is below 140/90 mm Hg, except 
in patients with diabetes or chronic renal disease, for whom a lower goal 
(130/80 mm Hg or lower) is advised.  
 
LIFESTYLE CHANGES 
The lifestyle modifications recommended for patients with isolated 
systolic hypertension are the same as those for patients with other forms of 
hypertension, including weight reduction, restriction of dietary sodium, 
adoption of the Dietary Approaches to Stop Hypertension (known as DASH) 
eating plan (a diet rich in fruits, vegetables, and low-fat dairy products and 
low in saturated and total fat), increased physical activity, and moderation of 
alcohol intake (no more than the equivalent of two drinks per day for men 
and one for women). These interventions not only reduce blood pressure but 
also favorably affect other risk factors for cardiovascular disease, such as 
dyslipidemia, abdominal obesity and diabetes that characterize the metabolic 
syndrome.71  
DRUG TREATMENT 
Five major classes of antihypertensive drugs are most useful: 
diuretics, -adrenergic blockers, angiotensin-converting–enzyme (ACE) 
inhibitors, angiotensin-receptor blockers, and calcium-channel blockers. 
Each has been shown in clinical trials to reduce cardiovascular events.72 
when used in recommended dosages; their mean effects on blood pressure 
are similar,73 although individual patients may have different responses to 
each drug. In approximately two thirds of patients with hypertension, two or 
more drugs will be required to achieve target blood-pressure levels.  
The current Joint National Committee guidelines70 recommend 
thiazide diuretics as initial drug therapy for most patients with hypertension, 
on the basis of their proven efficacy in reducing blood pressure and 
cardiovascular complications in clinical trials and their low cost. Other 
antihypertensive medications are preferred initially when there are certain 
coexisting conditions. For example, in patients with hypertension and 
chronic kidney disease, compelling evidence from clinical trials supports the 
use of either an ACE inhibitor or an angiotensin-receptor blocker,74 and for 
patients who have had myocardial infarction or heart failure, a beta-blocker 
and an ACE inhibitor are preferred.75 Elderly men with both hypertension 
and benign prostatic hypertrophy are often treated for urinary symptoms with 
an -1–receptor antagonist, which can help control the hypertension but may 
increase the risk of orthostatic hypotension. Nevertheless, despite some 
important differences between antihypertensive medications, the major 
benefits of therapy are related to the reduction of blood pressure rather than 
to other specific drug actions.  
Thiazide-type diuretics can induce carbohydrate intolerance and 
diabetes,76 effects that are greater in patients in whom hypokalemia 
develops.77 However, the clinical importance of such adverse effects is 
uncertain, given clinical trial data showing that thiazides are at least as 
effective as other drug classes in reducing the risk of complications from 
cardiovascular disease.78 The current debate over initial drug use 
notwithstanding, most patients with hypertension should end up receiving a 
diuretic as part of their regimen, since more than one drug is usually required 
to achieve blood-pressure control and since diuretics complement the action 
of the other drugs so well.  
The use of beta-blockers as first-line therapy for elderly patients with 
hypertension has been questioned recently. A meta-analysis of intervention 
trials for hypertension showed a 16% higher incidence of stroke among 
patients treated with traditional beta-blockers (primarily atenolol) than 
among those treated with other antihypertensive medications.79 The lesser 
benefit from beta-blockers could be related to a smaller reduction in blood 
pressure. In a recent study of patients treated with atenolol, blood pressure 
measured by standard cuff techniques overestimated the pressure reduction 
by 4.5 mm Hg as compared with aortic pressure calculated from applanation 
tonometry and radial-artery waveforms80; in contrast, with a calcium-channel 
blocker, ACE inhibitor, or diuretic agent, the effects on central aortic- and 
brachial-artery pressures were similar.81  
Initial therapy with beta-blockers in elderly patients should probably 
be limited to those with compelling indications, such as coronary heart 
disease, myocardial infarction, congestive failure or certain arrhythmias. No 
data is available yet on whether such restrictions should apply to the newer 
beta-blockers with peripheral vasodilator properties.  
STRATEGIES FOR IMPROVING BLOOD-PRESSURE 
CONTROL 
 
Inertia on the part of physicians and a reluctance to treat systolic 
hypertension are important factors limiting optimal control of blood 
pressure.82 Many physicians do not give adequate doses of antihypertensive 
medications or do not use a combination of drugs to achieve the target 
pressure. Factors that adversely affect adherence to treatment include 
inadequate patient education; lack of physician empathy and social support; 
the presence of coexisting diseases; complex dose regimens; problems with 
transportation of the patient and the cost of medications. Participation by 
ancillary staff, including nurse clinicians, physicians' assistants, and 
pharmacists, has been shown to be effective in improving blood-pressure 
control.83 Most elderly patients tolerate antihypertensive medications well, 
although a low starting dose and a gradual rate of increase in the dose (e.g., 
every 2 to 4 weeks) is prudent, particularly in frail and relatively immobile 
patients and in patients with diabetes, since both groups are at increased risk 
for orthostatic hypotension and associated falls.84  
GUIDELINES 
The Joint National Committee guidelines, which have been endorsed 
by several professional organizations, including the American Medical 
Association, the American Heart Association, and the American Society of 
Hypertension, recommend thiazide-type diuretics as initial drug therapy for 
most patients with isolated systolic hypertension unless there are specific 
contraindications for their use. Compelling indications discussed above 
warrant initiation of therapy with an ACE inhibitor, angiotensin-receptor 
blocker, calcium-channel blocker, or beta-blocker. The addition of a drug 
from another class is required if the target blood pressure is not achieved. 
The joint guidelines of the European Society for Hypertension and the 
European Society of Cardiology do not give preference to diuretics and 
recommend any of the five major classes of antihypertensive drugs for first-
line therapy.85 Recent guidelines from Great Britain argue against the use of 
both diuretics and beta-blockers for initial therapy and favor ACE inhibitors, 
angiotensin-receptor blockers, or calcium-channel blockers.86 Despite some 
differences in recommendations, all of these guidelines emphasize that the 
major benefits of therapy are related to lowering blood pressure and 
controlling hypertension. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 
 
 
Materials–Patients with Isolated Systolic Hypertension who attended      
Hypertension OP under institution of Kilpauk Medical 
College and Govt. Hospital were taken up. 
               
Study population included patients belonging to low socioeconomic 
urban or semi urban city of Chennai . 
Isolated Systolic Hypertension was defined as per JNC-7 guidelines 
 
The study group included  
 
1. Newly detected hypertensives with Isolated Systolic Hypertension. 
2. Control group with essential hypertension (Systolic and Diastolic 
Hypertension). 
 
Following group were excluded from the study. 
1. Patients with secondary form of hypertension  
2. Patients with Pre hypertension.  
Detailed evaluation of patients in terms of symptomatology, History, 
Clinical examination, and Laboratory data were carried out. The proforma 
used for the same is attached  
Once diagnosed, they were put on appropriate management. The 
treatment and outcome is not included in the study. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
DEFINITIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DEFINITIONS 
 
Essential Hypertension  
 The Seventh Report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure(2003) defines 
Essential Hypertension as Systolic Blood Pressure consistently 140 mmHg 
or greater, and diastolic blood pressure consistently 90 mmHg or greater in 
the absence of any evident cause. 
 
Isolated Systolic Hypertension 
 Isolated Systolic Hypertension (ISH) is defined as elevated Systolic 
Blood Pressure above 140 mm Hg in conjunction with Diastolic Blood 
Pressure below 90 mm Hg. 
 
Systolic Blood Pressure 
Systolic Blood Pressure is defined as the maximum arterial pressure 
during contraction of the left ventricle of the heart. 
 
Diastolic Blood Pressure 
Diastolic Blood Pressure is defined as the minimum arterial pressure 
during relaxation and dilatation of the left ventricle of the heart. 
Pulse Pressure  
 Pulse Pressure is defined as the change in blood pressure seen during 
contraction of the heart. It is the Systolic Pressure minus the Diastolic 
Pressure. 
Mean Arterial Pressure 
 The Mean Arterial Pressure (MAP) is defined as the average arterial 
pressure during a single cardiac cycle. It is the sum of Diastolic Blood 
Pressure and one-third of Pulse Pressure. 
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RESULTS AND ANALYSIS 
¾ 115 patients with isolated systolic hypertension were diagnosed among 
patients attending hypertension clinic and were included in study group 
during the period Aug 2006 - Jul 2007 
¾ 50 patients with essential hypertension group were attending 
hypertension clinic were included in the study to compare and analyze 
the determinants of isolated systolic hypertension. 
 
ANALYSIS OF CLINICAL PROFILE OF ISOLATED SYSTOLIC 
HYPERTENSION 
 
¾ Mean age of study population - 61.87 yrs. 
¾ Mean BMI – 25.39 kg/m2 
¾ Mean waist circumference – 85.57 cm 
 
Anthropometric analysis states that most of the patients were over weight                         
individuals. Most of them had increased waist circumference putting them to 
increased cardiovascular risks per modified ATP III criteria (≥85 cm) 
appropriate for Indians. 
 
 
 Commonest Symptoms No of Patients % 
Dyspnoea 42 36.5% 
Giddiness 22 19.1% 
Angina 16 13.9% 
Edema 11 9.5% 
Headache 9 7.8% 
Oliguria 5 4.3% 
 
37 Patients ( 32.17 %) had h/o DM 
13 Patients ( 11.3 %) had family history of Hypertension 
13 Patients ( 11.3 %) had pedal edema 
63 Patients ( 54.7 %) were overweight BMI (25-29.9) 
4 Patients ( 3.4 %) were obese (>30) 
11 Patients ( 9.5 %) had I fundus changes 
  1 Patients ( 0.8 %) had II fundus changes 
34 Patients ( 29.5 %) had LVH and Hypokinetic changes in echocardiogram 
10 Patients ( 8.69 %) had abnormal kidney echoes  
 
37 Patients ( 32.17 %) had Hb % < 10 gm/day 
37 Patients ( 32.17 %) had casual glucose > 200 
 9 patients ( 7.8 %) had serum calcium level >10.5 mg/dl 
 6 patients ( 5.2 %) had serum uric acid level >6 mg/dl 
 2 patients ( 1.7 %) had serum sodium level >144 Meq/dl  
 2 patients ( 1.7 %) had serum potassium level >5.5 Meq/dl  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total Cholesterol           n - no. of patients 
Borderline 
(200-239 mg/dl) 
n = 42 36.5% 
Undesirable 
>240 mg/dl 
n = 34 29.56% 
 
LDL                                 n - no. of patients 
Borderline 
(130-159 mg/dl) 
n = 30 26.08% 
Undesirable 
>160 mg/dl 
n = 40 34.78% 
 
HDL                                n - no. of patients 
Borderline 
(40-60 mg/dl) 
n = 82 71.30% 
Undesirable 
>40 mg/dl 
n = 30 26.08% 
 
 
TGL n - no. of patients  
Abnormal 
(>160) mg/dl) 
n = 35 30.43% 
        
 
 
ISOLATED SYSTOLIC HYPERTENSION  
SUMMARY STATISTICS FOR CONTINUOUS VARIABLES  
 
Sl. No ITEMS MEAN MEDIAN (RANGE) 
        
1 AGE 62.41 62   (42-77) 
2 BMI 25.39 26.5   (17.32) 
3 SYS BP 168.92 168  (144-280) 
4 DBP 79.87 80   (70-90) 
5 PULSE PRESSURE 88.38 88   (56-126) 
6 MAP 109.31 109.3   (94.6-123.3) 
7 HB 11.05 10.5   (7.4-12.8) 
8 ESR 17.42 14   (5-92) 
9 BL SUGAR 161.43 125   (71-312) 
10 UREA 30.45 28   (15-112) 
11 CREATININE 0.95 0.9   (0.4 - 3.0) 
12 NA+ 137.53 138   (130-147) 
13 K+ 4.2 4.2   (3.0 - 5.7) 
14 TOTAL CHOLES 218.9 219  (126-316) 
15 TGL 139.66 132   (60-240) 
16 HDL 46.20 46   (33-66) 
17 VLDL 27.84 27   (12-46) 
18 LDL 35.01 142   (42-220) 
19 SE CALCIUM 9.46 9.4   (8.3-10.8) 
20 SE URIC ACID 3.73 3.4  (2.0 - 11.0) 
 
 
ANALYSIS OF THE DETERMINANTS OF ISOLATED SYSTOLIC 
HYPERTENSION 
TABLE – 1: AGE DISTRIBUTION - ANALYSIS 
Age ISH EHT 
<50 yrs 6(5.2%) 4(8%) 
51-60 yrs 27(23.4%) 23(46%) 
61-70 yrs 69(60%) 20(40%) 
>71 13(11.3%) 3(6%) 
 115 50 
 
TABLE – 2: AGE DISTRIBUTION – ANALYSIS 
Category No. of Patients Mean S.E of Mean 
ISH 115 62.41 0.5857 
EHT 50 59.26 0.94450 
 
   P = 0.00411   ‘P’ value is significant 
Interpretation: 
 Among the 115 patients with Isolated Systolic Hypertension studied, 
the age incidence was highest in the 61- 70 year age group (60%). This was 
followed by 51- 60 year age group (23.4%). 
 
TABLE – 3: SEX DISTRIBUTION – ANALYSIS 
 
P = 0.028877  ‘P’ value is significant 
Interpretation: 
 Among the 115 patients with Isolated Systolic Hypertension studied, 
females form the majority. This is also true when compared with 50 patients 
with Essential Hypertension 
 
 
 
 
 
 
 
 
 
Category ISH 
(no. of patients) % 
EHT 
(no. of patients) % 
Male (39) 33.9% (26) 52% 
Female (76) 66.08% (24) 48% 
 115 50 
TABLE – 4: SYMPTOM – ANALYSIS 
Isolated Systolic Hypertension 
SYMPTOMS 
Shortness of Breath 
PERCENTAGE 
36.5% 
Giddiness 19.1% 
Angina 13.9% 
Edema 9.5% 
Headache 7.8% 
 
Interpretation: 
 Among the 115 patients with Isolated Systolic Hypertension studied, 
36.5% complained of shortness of breath followed by giddiness (19.1%). 
 
 
 
 
 
 
 
 
 
TABLE – 5: SMOKING – CORRELATION 
 
Category 
ISH 
No. of Patients 
EHT 
No. of Patients 
Non-Smokers 88 39 
Smokers 27 11 
 115 50 
 
P = 0.140682 ‘P’ value is not significant 
Interpretation: 
 Among the 115 patients with Isolated Systolic Hypertension studied, 
27 (23.4%) cases have history of smoking  
 Among the 50 patients with Essential Hypertension 11 (22%) cases 
have history of smoking when compared smoking is not a major factor in the 
occurrence of Isolated Systolic Hypertension. 
 
 
 
 
 
 
 
TABLE – 6: BODY MASS INDEX (BMI) – CORRELATION 
 
Category No. of Patients  Mean S.E of Mean 
ISH 115 25.39913 0.30117 
EHT 50 24.862 0.45719 
 
P = 0.327816 ‘P’ value is not significant 
Interpretation: 
 The mean BMI in the ISH group is 25.39913 
 The mean BMI in the EHT group is 24.862 
The baseline BMI is not a major factor in the occurrence of Isolated 
Systolic Hypertension. 
 
 
 
 
 
 
 
 
 
 
TABLE – 7: SYSTOLIC BLOOD PRESSURE (SBP) – CORRELATION 
 
Category No. of Patients Mean S.E of Mean 
ISH 115 168.9217 1.708647 
EHT 50 176.64 2.205329 
 
P = 0.010277   ‘P’ value is significant 
Interpretation: 
 Among the 115 patients with Isolated Systolic Hypertension studied, 
the mean SBP is 168.9217. Among the 50 patients with Essential 
Hypertension, the mean SBP is 176.64. 
On analyzing, the Systolic Blood Pressure has a positive correlation 
with the incidence of Isolated Systolic Hypertension 
 
 
 
 
 
 
 
 
 
TABLE – 8: DIASTOLIC BLOOD PRESSURE (DBP) – CORRELATION 
 
Category No. of Patients Mean S.E of Mean 
ISH 115 79.87 0.6294 
EHT 50 103.72 1.093222 
 
P = 0.0000    ‘P’ value is significant 
Interpretation: 
 The mean DBP in the ISH group 79.87  
 The mean DBP in the EHT group 103.72  
Thus, the diastolic pressure has a definite correlation in the occurrence 
of Isolated Systolic Hypertension. 
 
 
 
 
 
 
 
 
 
 
TABLE – 9: PULSE PRESSURE (PP) – CORRELATION 
 
Category No. of Patients Mean S.E of Mean 
ISH 115 88.382 1.6368 
EHT 50 72.92 2.4771 
 
P = 0.00001   ‘P’ value is significant 
Interpretation: 
 The mean pulse pressure is increased in the Isolated Systolic 
Hypertension group compared to the Essential Hypertension group and is 
statistically significant. Hence, the Pulse Pressure determines the occurrence 
of Isolated Systolic Hypertension. 
 
 
 
 
 
 
 
 
 
TABLE – 10: MEAN ARTERIAL PRESSURE (MAP) – CORRELATION 
 
 
  P = 0.0000  ‘P’ value is significant 
Interpretation: 
 The mean MAP (Mean Arterial Pressure) is reduced in Isolated 
Systolic Hypertension group when compared to the Essential Hypertension 
group and is statistically significant. Hence, the MAP determines the 
occurrence of Isolated Systolic Hypertension. 
 
 
 
 
 
 
 
 
 
Category No. of Patients Mean S.E of Mean 
ISH 115 109.31 0.5997 
EHT 50 128.19 1.0441 
TABLE – 11: BLOOD GLUCOSE – CORRELATION 
 
Category No. of Patients Mean S.E of Mean 
ISH 115 161.4348 6.96 
EHT 50 188.9 1212716 
 
  P = 0.039595  ‘P’ value is significant 
Interpretation: 
 The mean blood glucose level in the ISH group is 161.4348 
 The mean blood glucose level in the EHT group is 188.9 
Thus, the increase in blood glucose level favors the occurrence of 
Essential Hypertension rather than Isolated Systolic Hypertension. 
 
 
 
 
 
 
 
 
 
 
TABLE – 12: TOTAL CHOLESTEROL – CORRELATION 
 
Category No. of Patients Mean S.E of Mean 
ISH 115 218.9043 4.9858 
EHT 50 229.14 5.5650 
 
P = 0.225345  ‘P’ value is not significant 
Interpretation: 
 The mean total cholesterol in the ISH group is 218.9043 
 The mean total cholesterol in the EHT group is 229.14 
Thus, the baseline cholesterol level does not correlate with the 
occurrence of Isolated Systolic Hypertension. 
 
 
 
 
 
 
 
 
 
TABLE – 13: SERUM SODIUM – CORRELATION 
 
Category No. of Patients Mean S.E of Mean 
ISH 115 137.539 0.4143 
EHT 50 137.6 0.6546 
 
P = 0.936452  ‘P’ value is not significant 
 
TABLE – 14: SERUM POTASSIUM – CORRELATION 
 
Category No. of Patients Mean   95% C.I 
ISH 115 4.201   4.077       4.326 
EHT 50 4.148  3.948        4.347 
 
P = 0.642373  ‘P’ value is not significant 
 
Interpretation: 
Thus, the baseline serum sodium and serum potassium level does not 
correlate with the occurrence of Isolated Systolic Hypertension. 
 
 
LCL UCL 
TABLE – 15: SERUM CALCIUM – CORRELATION 
 
Category No. of Patients Mean   95% C.I 
ISH 115 9.466   9.360       9.572 
EHT 50 9.772  9.598        9.945 
P = 0.002368  ‘P’ value is significant 
Interpretation: 
The increase in serum calcium level favors the occurrence of Essential 
Hypertension rather than Isolated Systolic Hypertension. 
 
TABLE – 16: SERUM URICACID – CORRELATION 
 
Category No. of Patients Mean S.E of Mean 
ISH 115 3.737 0.1440 
EHT 50 4.226 0.3031 
 
P = 0.100521  ‘P’ value is not significant 
Interpretation: 
Thus, the baseline serum uricacid level does not correlate with the 
occurrence of Isolated Systolic Hypertension. 
 
LCL UCL 
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DISCUSSION 
 
Isolated Systolic Hypertension is a common disorder in the elderly, 
carrying with it a high risk of cardiovascular morbidity and mortality 
Analyzing age distribution ISH is more common in 61-70 years age 
group (60%). ISH incidence increases from 50 years of age and maximum 
incidence is 61-70 years age group. This suggests that increasing age 
determines the occurrence of Isolated Systolic Hypertension. This is similar 
to the Framingham Heart Study analysis by Van B Welking, Al Belanger 
MA which shows ISH in 57.4% in men > 65 years87. This study also 
represents that ISH is the frequent form of hypertension among older 
individuals. 
Among the 115 patients with Isolated Systolic Hypertension studied 
females (66.08%) form the dominant group then the males (33.9%). This is 
again confirmed by a comparative study of patients with Essential 
Hypertension and was statistically significant using a paired ‘t’ test with a 
‘P’ value of 0.028877. The Chennai Urban Rural Epidemiology Study 
(CURES-52) states that women had a higher prevalence of isolated systolic 
blood pressure compared to men. 
 
The SHEP (Systolic Hypertension in the Elderly Program) similarly 
shows a high prevalence of ISH in older adults especially in older women88 . 
Moreover, after menopause, there is a sharp increase in the prevalence of 
hypertension in women to levels that equal or surpasses that of men. This is 
because of the protection afforded by the ovarian hormones to the pre-
menopausal women89 . These may be the reasons for higher prevalence of 
Isolated Systolic Hypertension among older women in our study.  
The chief symptom in the Isolated Systolic Hypertension in our study 
is shortness of breath (36.5%) followed by giddiness (19.1%). Christopher J. 
Bulpitt, Astrid E. Fletcher in a study based on the SYST-EUR Trial also 
states that unsteadiness, nocturia and headache occur in excess in untreated 
Isolated Systolic Hypertension. 
The base line mean BMI in the ISH group is 25.39913 and mean BMI 
in the Essential Hypertension group is 24.862. When analyzed statistically 
using paired ‘t’ test, it is not significant. The lack of association of baseline 
BMI with the incidence of ISH in our study is supportive of a cross-sectional 
Mexican survey,90 which failed to show a significant association of excess 
body weight with ISH. Jose R. Pio, BS; Nathan D. Wong, PhD in a study 
also quotes that BMI at baseline was not a predictor of ISH.  
Analyzing the Systolic Blood Pressure (SBP) in the Isolated Systolic 
Hypertension group and in the Essential Hypertension group it was found 
that SBP is positively related to the development of ISH. This is also 
statistically significant using a paired ‘t’ test with a ‘P’ value of 0.010277. 
Studies of elderly subjects with isolated systolic hypertension showed  
.that increased input impedance (large artery stiffness and early pulse 
wave reflection) ‘predominated’ over increased vascular resistance.91 In 
addition, a computer simulation of a modified Windkessel model for 
geriatric isolated systolic hypertension indicated that vascular resistance 
increased by only 25%, whereas there was a 50% to 75% increase in input 
impedance secondary to large artery stiffness and early wave reflection.92 
These conclusions are further supported by the observed decrease in DBP 
and increase in SBP after age 60 in the Framingham subjects. 
The mean DBP in the Isolated Systolic Hypertension group is 79.87 
and in the Essential hypertension group is 103.72 which is statistically 
significant with the ‘P’ value of 0.000. The decline in DBP seen in the 
elderly is probably the result rather than the cause of the disease process. 
Age-related stiffening of the aorta is associated with a decreased capacity of 
the elastic reservoir and hence a greater peripheral runoff of stroke volume 
during systole. The exaggerated fall in DBP seen in elderly hypertensive 
subjects suggests a process of transmural pressure-induced arterial wall 
damage resulting in large artery stiffness.93 The most likely explanation, 
therefore, for the fall in DBP after age 60 years is increased large artery 
stiffness.94 Our study also supports the concept of an interaction between 
aging and hypertension in the progressive fall of DBP and rise of SBP. 
The mean pulse pressure is increased in the Isolated Systolic 
Hypertension group compared to the Essential Hypertension group in our 
study. This is statistically significant using paired ‘t’ with a ‘P’ value of 
0.00001. This is similar to the study quoted by Nichols WW, O'Rourke MF. 
based on the Framingham Heart Study. The most plausible explanation 
given by them for both the late rise in Pulse Pressure and fall in Diastolic 
Blood Pressure is an increase in the large artery stiffness caused by intrinsic 
structural abnormalities95. 
The mean MAP (Mean Arterial Pressure) is reduced in Isolated 
Systolic Hypertension group when compared to the Essential Hypertension 
group in our study. This is similar to the study quoted by Messerli FH, 
Sundgaard-Risse K, Ventura HO state that the leveling off of MAP after age 
50 to 60 years in all SBP groups in the above study suggests that vascular 
resistance is underestimated in older persons, since there is firm evidence 
that vascular resistance continues to rise with aging.96. 
Baseline heart rate, total cholesterol, blood glucose, and smoking were 
not predictive of ISH incidence as quoted by Stanley S. Franklin, MD; 
William Gustin, IV, BS. This is similar to our study when analyzed 
statistically between the Isolated Systolic Hypertension group and the 
Essential Hypertension group. 
Thus, our study shows that Isolated Systolic Hypertension is a definite 
clinical entity and not a benign consequence of aging.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
 
1. Isolated Systolic Hypertension is not an inevitable consequence of 
aging; rather it is the endpoint of several contributing factors. 
2. Increasing Age and Female Preponderance are the most significant 
variables in the evolution of Isolated Systolic Hypertension. 
3. The Blood Pressure components namely Systolic and Diastolic 
Blood Pressure, Pulse Pressure and Mean Arterial pressure 
influence the occurrence of Isolated Systolic Hypertension.  
4. Baseline cholesterol and Baseline Blood glucose were not 
predictive of Isolated Systolic Hypertension incidence but may 
influence and contribute in due course. 
5. Similarly Smoking and BMI were also not predictive of Isolated 
Systolic Hypertension incidence. 
6. Since Isolated Systolic Hypertension is a definite clinical entity, it 
is important to study the determinants and pay more attention to 
the diagnosis and treatment of the same. 
Limitations of the study 
• Small Sample Size 
• Baseline Parameters were only used to assess the 
determinants of Isolated Systolic Hypertension.  
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ANNEXURES 
 
 
 
 
 
 
 
 
 
 
ABBREVIATIONS 
 
 
 
ISH    :  Isolated Systolic Hypertension 
 
EHT    :  Essential Hypertension 
 
SBP    :  Systolic Blood Pressure 
 
DBP    :  Diastolic Blood Pressure  
 
PP    :  Pulse Pressure 
 
MAP    :  Mean Arterial Pressure 
 
TOD    :  Target Organ Damage 
 
CV-RISK   :  Cardiovascular Risk 
 
AGE    :  Advanced Glycation End products 
 
 
 
 
 
 
 
PROFORMA 
 
CLINICAL PROFILE OF ISOLATED SYSTOLIC HYPERTENSION 
 
  
No…          HTN Clinic No… 
 
Name:                       Age:              Sex: 
 
Address:          Education/Occupation 
 
Phone.No.: 
 
 
COMPLAINTS: 
 
Head ache   :  Y/N 
Giddiness   :  Y/N 
Palpitations   :  Y/N 
Angina   :  Y/N 
Dyspnoea   :  Y/N 
Syncope   :  Y/N 
Edema   :  Y/N 
Oliguria   :  Y/N 
Limb weakness  :  Y/N 
Epistaxis   :  Y/N 
 
 
PAST HISTORY:  DM/Smoking/Alcohol/Drug intake 
 
 
FAMILY HISTORY OF HYPERTENSION: 
 
 
EXAMINATION: 
 
Wt (kg):     Waist circumference (cm): 
 
Ht (cm):     BMI(kg/m2): 
 
 
Pallor/Juandice/Cyanosis/Clubbing/Edema/Lymphadenopathy 
 
Pulse (per min):     Peripheral Pulse:  
 
 
BP   UL(R):    UL(L): 
  mm/Hg    mm/Hg 
 
 
  Supine:    Standing: 
  mm/Hg mm/Hg 
 
JVP : 
 
CVS : S1   S2    Added sounds 
 
RS : Breath Sounds 
  Crepts/Rhonchi 
 
ABD : Aortic Pulsations 
  Bruit 
 
CNS :   FUNDI : 
 
 
INVESTIGATIONS: 
 
 Hb(%)   Urine ALB: 
 ESR   ECG: 
 RBS   ECHO: 
 UREA   USG ABD: 
 CREATININE  Others: 
 Na+    
 K+ 
 Total Cholestrol 
 LDL 
 HDL 
 TGL 
 VLDL 
 Se.Calcium 
 Se.Uric acid 
 
 
COMMENTS: 
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ISH - AGE    DISTRIBUTION
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< - 50 Yrs
51 - 60 Yrs
61 - 70 Yrs
> - 70 Yrs
CHART - I
5.2%
23.4%
60%
11.3%
AGE IN YEARS
66.08% 48%
33.90% 52%
FEMALE MALE FEMALE MALE
66.08%
33.90%
FEMALE MALE
48%
52%
FEMALE MALE
SEX DISTRIBUTION - ISH SEX DISTRIBUTION - EHT
CHART - II
SYMPTOM   -  ANALYSIS
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36.5%
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13.9%
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7.8%
SHORTNESS OF BREATH
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ANGINA
EDEMA
HEADACHE
SHORTNESS 
OF BREATH
GIDDINESS ANGINA EDEMA HEADACHE
CHART - III


SMOKING MOTHER FATHER BOTH
1 Mariammal 4207/06 60  F - - - + - - - - - - -
2 Lakshmi 4322/06 62 F + + - - + - - - - - -
3 Muthu Krishnan 5016/07 67 M - - - - + - - + - - -
4 Prema 4262/06 62 F + - - - - - - - - - -
5 Nagaraj 5112/06 64 M - + - - - - - + - - -
6 Manonmani 4587/06 53 F - + - - - - - - - - -
7 Annal 5011/06 61 F - - - + + - - - - - +
8 Ramanujaya 4628/06 60 M - - - + + - - + + - -
9 Arasalli 4325/07 62 F + - - - + - - - - - -
10 Gloria 4901/07 68 F - - - - + + - - + - -
11 Saradha 4100/06 68 F - - - - - - - - - - -
12 Ellappan 4801/06 63 M + - - + - - - + - - -
13 Kanaga 4315/06 66 F - - - - - - - - - - +
14 Murugesan 5207/07 53 M - + - - - - - + - - -
15 Kannama 4208/06 66 F - - - - - - - - - - -
16 Sundari 4626/07 61 F - - - - - - - - - - -
17 Rajalakshmi 4173/07 64 F - - - - + - - - - - -
18 Banumathi 4386/06 62 F - - - - - - - - - - -
19 Thangaraj 4426/07 44 M - - - - - - - + - - -
20 Vadevelu 4465/06 66 M - - - - - - - + - - -
21 Kamatchi 4109/07 54 F - - - - + - - - - - -
22 Kannagi 4300/07 52 F - + - - - - - - - - -
23 Madhavan 4269/06 68 M - + - + - - - + + - -
24 Chandra 4613/07 69 F - - - + - - - - - - -
25 Sivagami 5316/06 51 F - - - - + - - - - - -
MASTER CHART
ISOLATED SYSTOLIC HYPERTENSION GROUP
Total no of patients 115 
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26 Kanthal 4529/06 61 F - - - - + + - - + - -
27 Lakshmanan 4209/07 57 M - - - - - - - + - - +
28 Muniyama 4258/07 64 F - - - - + - - - - - -
29 Leelavathy 4297/06 47 F + - - - + - - - - + -
30 Sekar 4397/06 61 M - - + - - - - + - - -
31 Mani 4912/07 73 M - - - - - - + + - - -
32 Mrs. Begam 4656/07 63 F - + - - - + - - - - -
33 Magadevi 4928/07 62 F - - - - - - - - - - -
34 Vasuki 4971/06 60 F - - - - - + - - + - +
35 Meenakshi 5125/06 65 F - - - - + - - - - - -
36 Srinivasan 4375/07 56 M - + - + + - - + - - -
37 Prema 5248/07 64 F - - - - - - - - - - -
38 Ellamma 5341/06 66 F - - - - + - - - - - -
39 Kamala veni 4791/07 67 F - - - + - - - - - - -
40 Lakshmi 5314/06 72 F - - - - + - - - - - -
41 Andal 4257/07 62 F - - - - - - - - - - -
42 Narmadha 4199/06 71 F - - - + - - - - - - -
43 Ragubai 4766/06 62 F - + - - + - - - - - -
44 Nagaraj 4329/07 60 M - + - - + - - + - - -
45 Lazar 4587/07 62 M - - - - - + - - - - -
46 Kanthimathy 4352/06 55 F - - - - + + - - + - -
47 Rani 4365/06 66 F - - + - - - - - + - -
48 Logasan 5128/06 64 M + + - - + + - + + - -
49 Ellappan 5397/07 77 M - - - - - - - - - + -
50 Eswari 5122/07 67 F + - - - - + - - - - -
ISOLATED SYSTOLIC HYPERTENSION GROUP
Total no of patients 115 
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51 Muniyamal 4813/07 71 F - - - - - - - - - - -
52 Indirani 4355/06 62 F - + - + - - - - - - +
53 Lakshmi 4566/07 63 F - + - - - - + - - - -
54 Kalavathi 5312/06 67 F - - - - + - - - - - -
55 Sudha 4379/06 65 F - - - - + - - - - - -
56 Eswaran 4987/06 56 M - - - - + - - + - - -
57 Marudhu 4123/0 63 M - - - - - - - + - - -
58 Sakunthala 5513/07 62 F - - - - - - - - - - -
59 Arasalli 5397/06 60 F - - - - - - - - - - -
60 Annammal 4923/06 58 F - - - - + - - - - - -
61 Muthu 4377/06 62 M - - - - - - - - - - -
62 Krishnan 4982/07 60 M - + - - - - - + - - -
63 Chandra 4568/06 72 F - + - - + - - - - - -
64 Arunadevi 4123/06 47 F - - - - + - - - - - -
65 Gloria 4378/07 62 F - - - - - - - - - - -
66 Ganthimathy 5379/06 60 F - - + - + - - - - + -
67 Lakshmipriya 4987/06 61 F - - - - - - - - - - -
68 Sarojini 4569/07 57 F - - + - - - + - - + -
69 Sundram 4658/07 63 M - - - - - + - - - - -
70 Muralidharan 4172/06 64 M - - - - - - - - - - -
71 Thangaraj 4293/07 66 M - + - - - + - + - - -
72 Chinnamal 4168/06 62 F - + - - + - - - + - -
73 Balammal 4912/06 72 F - - - - - - + - - - -
74 Kamatchi 4567/07 52 F - - - + + - - - - - -
75 Parvathy 4321/06 72 F - - - + - - - - - - -
Total no of patients 115 
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No.
AGE 
(yrs)
SYMPTOMS FAMILY H/O HTN
P
A
L
P
I
T
A
T
I
O
N
G
I
D
D
I
N
E
S
S
A
N
G
I
N
A
D
Y
S
P
N
O
E
A
E
D
E
M
A
O
L
I
G
U
R
I
A
H
E
A
D
A
C
H
E
G
E
N
D
E
R
SMOKING MOTHER FATHER BOTH
76 Kasthuri 4654/06 73 F - + - - + - - - - - -
77 Lakshmi 4789/06 62 F - - - - - - - - - - -
78 Vadivelu 4895/06 55 M + - - - + - - + - - -
79 Chinathai 5378/07 63 F - - - - - - - - - - +
80 Rajendran 5198/07 72 M - - - - + - - - - - -
81 Shankaran 5346/07 63 M - - - - - - - + - - -
82 Pattammal 4912/06 63 F - - - - + - - - - - -
83 Jaya 4852/07 64 F - - - - - - - - - - -
84 Yasodha 4951/06 72 F - - - - + - - - - - -
85 Murugan 5375/06 60 M - + - - - - - - - - -
86 Saradha 5295/07 62 F - - - - - - - - - - -
87 Vijayalakshmi 5468/07 61 F - - - - + - - - - + -
88 Marimuthu 4288/07 65 M - + - - - - - + - - -
89 Chinnaiyan 4333/07 66 M - - - - - - + - - - -
90 Kannambal 5247/06 53 F - - - - + - - - - - -
91 Kanaga 4287/06 68 F - - - - + - - - - - -
92 Vasuki 4255/06 60 F - - + - + - - - - - -
93 Sadhasivam 4978/06 62 M - - - - - - - - + - -
94 Balan 4567/07 68 M - - - - - - - - + - -
95 Duraimurugan 4458/07 54 M - - - + - - - + - - -
96 Valli 4192/06 60 F - - - + - - - - - - -
97 Thenmozhi 4668/06 74 F - - - - - - - - - - -
98 Vanitha 5138/06 62 F - - - - - + - - - - -
99 Kanagasabai 5299/06 42 M - - - - - - - + - - -
100 Naga lakshmi 4511/06 68 F - - - - - - - - - - -
ISOLATED SYSTOLIC HYPERTENSION GROUP
Total no of patients 115 
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SMOKING MOTHER FATHER BOTH
101 Shankaran 4311/06 66 M - - - - + - - - - - -
102 Ganesh 4655/06 62 M - - - - - - - + - - -
103 Lakshmi 4243/06 68 F - + - - + - - - - - -
104 Kamakshi 5100/07 52 F - - - - - - - - - - -
105 Vaasugi 4352/06 61 F - - - - - - - - + - -
106 Maariammal 5210/07 68 F - - - + - - - - - - -
107 Murugesan 4265/06 51 M - - - - - - - + - - -
108 Chinna ponnu 4987/07 64 F - + - + + - - - - - -
109 Valliammal 4253/06 58 F + - - - - - - - - + -
110 Manikam 4761/06 65 M - - - - - - - - - - -
111 Kasturi 5302/07 65 F - - - - - - - - - - -
112 Saraswati 4523/06 63 F - - - - + - - - - - -
113 Bala krishnan 4130/06 72 M - - - - - - - + - - -
114 Meenakshi 4634/06 60 F - - - - - - - - - - -
115 Kanniappan 4967/06 66 M - - - - - - - + - - -
Total no of patients 115 
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SMOKING MOTHER FATHER BOTH
1 Nagaraj 4212/07 65 M - - - - - - - + - - -
2 Kandhan 4294/07 62 M + - - - + - - - - - -
3 Mariappan 4256/06 65 M - + - - - - - + - - -
4 Chinnathai 4975/06 53 F - - - + - - - - - - -
5 Muniammal 4263/07 60 F + + - - + - - - - + -
6 Velayudham 4350/06 58 M - + - - + - - + - - -
7 Paremeswari 4259/06 62 F - - + - - + - - - + -
8 Koteeswaran 4213/07 66 M - + - - - - - - - - -
9 Valliammal 4358/07 57 F - + - - + - - - - - -
10 Shanmugam 4453/07 42 M + - - - - - - + + - -
11 Meenakshi 4718/06 65 F - - - - - - + - - - -
12 Vijaya 4968/07 58 F - + - - + - - - - + -
13 Kamakshi 4720/06 64 F - - - - - - - - - + -
14 Eswarammal 5200/07 60 F - + - + + - - - - - -
15 Kondammal 4281/06 57 F + - + - - + - - - - -
16 Annamal 5145/07 62 F - + - - - - - - + - -
17 Deenadayalan 4265/06 48 M - + - - - - - - - - -
18 Saradhamal 5051/07 67 F - - - - + - - - - - -
19 Sugumari 4214/06 58 F + - - - + - - - + - -
20 Jagadeswari 4390/07 36 F - - - + + - - - - - -
21 Sundaram 4512/06 65 M - + - - - - - - - - -
22 Saranya 4554/07 59 F - + - - - - - - - + -
23 Ellappan 4359/06 56 M - - - - - - - + - - -
24 Munian 4225/06 52 M - - - - - - - + + - -
25 Senthamarai 4455/07 52 F + - - - - - - - - - -
ESSENTIAL HYPERTENSION GROUP
Total no of patients 50
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SMOKING MOTHER FATHER BOTH
26 Kesawan 4348/07 66 M - + - - - - - + - - -
27 Annakili 5015/07 53 F + - - - + - - - - - -
28 Mangammal 4549/07 65 F - + - - - - - - + - -
29 Balakrishnan 4910/06 62 M - + - - + - - - - - -
30 Govendammal 4215/06 60 M + - + - - - - - - - -
31 Rajalakshmi 4350/07 64 F - - - - - - - - - - -
32 Shanmugam 4141/07 63 F - - - - + - - - - - -
33 Shankaran 4345/07 67 M - + - - + - - + - - -
34 Parijadham 4040/07 55 F - - - - - - - - + + +
35 Vadivelu 4559/06 60 M - + - - - - - + - - -
36 Mallayan 4916/06 65 M - - - + - - - - - - -
37 Kannaiyan 4725/06 59 M + - - - - - - - + - -
38 Sadasivam 4216/07 55 M - - - - + - - - - - -
39 Frameis 4347/06 50 M - + - - + - + - - - -
40 Leelavathi 4475/06 68 F + - - - - - - - - + -
41 Lakshmiammal 4550/06 55 F - + - - - - - - - - -
42 Thangaraj 4549/07 58 M - + - - - - - - - - -
43 Nagammal 4963/07 60 M - - - - - - - - - - -
44 Vasuki 4723/07 65 F + - - - + - - - - - -
45 Chennappan 4545/06 63 M - - - - - - - - - - -
46 Velmurugan 4716/07 58 M - + - - + - - - + + +
47 Iyyanar 4226/07 57 M - - - - - - - - - - -
48 Pandian 4964/07 65 M + - - - - - - - - - -
49 Rajarathnam 4612/06 62 M - - - - + - - + - - -
50 Ganesan 4925/06 64 M - - - - - - - + - - -
Total no of patients 50
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ABBREVATIONS:
(+)  - POSITIVE
( - )  - NEGATIVE
HK   - HYPOKINESIA (ECHO)
LVH  - LEFT VENTRICULAR HYPERTROPHY (ECHO)
    K      -     KIDNEY   ECHOES
    K      -     KIDNEY   ECHOES
FL  -  FATTY LIVER
CL  -  CHOLELITHIASIS
WT  -  WEIGHT
HT   -  HEIGHT
BMI  - BODY MASS INDEX
JVP - JUGULAR VENOUS PRESSURE
HB  - HAEMOGLOBIN
ESR  - ERYTHROCYTE SEDIMENTATION RATE
Na +  - SERUM SODIUM
K +   - SERUM POTASSIUM
CHOLES  - CHOLESTEROL
TGL   - TRIGLYCERIDES
HDL  - HIGH DENSITY LIPOPROTEIN
VLDL - VERY LOW DENSITY LIPOPROTEIN
LDL  - LOW DENSITY
ALB - ALBUMIN
1 69.1 160 27 89 - - 78 156 80 76 105.3 -
2 48 152 20.7 78 - - 72 180 72 108 108 -
3 64 155 26.6 87 - - 82 148 80 68 102.6 -
4 63 162 24 84 - + 86 172 80 92 110.6 I
5 61 153 26 78 + - 88 150 70 80 96.6 -
6 65 151 28.5 91 - - 74 190 80 110 116.6 -
7 68 160 26.5 80 - - 78 150 82 68 104.6 -
8 60 158 24 88 - + 80 158 70 88 99.3 -
9 66 153 28.1 86 - - 90 160 70 90 100 -
10 60 160 23.4 86 - - 60 186 72 114 110 -
11 35.7 145 17 79 - - 80 200 80 120 120 -
12 52 157 21 81 - - 72 170 90 80 116.6 -
13 68 166 24.6 92 - - 78 144 70 74 94.6 I
14 67 154 28.2 85 - - 64 164 84 80 110.6 -
15 55 162 21 88 - - 78 150 74 76 99.3 -
16 70 156 28.7 83 - - 72 170 90 80 116.6 -
17 78 170 26.9 79 - - 64 184 76 108 112 -
18 52 161 20 88 - - 74 170 82 88 111.3 -
19 65 155 27 90 - - 76 168 80 88 109.3 -
20 74 167 26.5 85 - - 82 180 70 110 106.6 -
21 59 157 23.9 85 - - 82 156 72 84 100 -
22 70 156 28.7 90 - - 64 172 88 84 116 -
23 60 165 22 81 + - 84 170 76 106 111.3 -
24 72 158 28.8 89 - - 78 150 90 60 110 -
25 47 146 22 91 - - 66 180 80 100 113.3 -
MASTER CHART
ISOLATED SYSTOLIC HYPERTENSION GROUP
Total no of patients 115 
DBP  
(mmHg) 
PULSE 
PRESSURE 
(mmHg) 
MAP 
(mmHg) FUNDUSJVP EDEMA
PULSE   
(per min)
SBP  
(mmHg)    
WT        
(kg)
HT        
(cm)
BMI   
(kg/m2)
WAIST  
(cm)
Sl. 
No.
26 67 152 28.9 90 - + 80 164 80 84 108 I
27 51 160 19.9 80 - + 90 158 90 68 112.6 -
28 69 164 25.6 79 - - 76 162 82 80 108.6 -
29 48 159 19 86 - - 84 170 70 100 103.3 I
30 73 164 27.1 92 - - 92 154 80 74 104.6 -
31 49 157 20 87 - - 72 180 80 100 113.3 -
32 67 155 27.8 84 - - 76 176 80 96 112 -
33 70 163 26.3 88 - - 86 154 84 70 107.3 -
34 52 147 24 88 - + 78 152 76 76 101.3 -
35 53 155 22 85 - - 92 182 78 104 112.6 -
36 75 165 27.5 82 - - 88 148 90 58 109.3 -
37 54 150 24 78 - - 78 190 90 100 123.3 -
38 80 171 27.3 89 - - 100 150 80 70 103.3 -
39 68 156 27.9 76 - - 80 186 70 116 108.6 -
40 48 151 21 87 - - 94 280 80 120 120 -
41 55 162 21 83 - - 90 160 82 78 108 -
42 46 148 21 81 - - 76 146 90 56 108.6 I
43 66 155 27.4 85 - - 98 176 80 96 112 -
44 70 160 27.3 84 - - 72 174 70 104 104.6 -
45 63 162 24 88 - - 74 152 76 76 101.3 -
46 72 161 27.7 89 - - 88 156 84 72 108 -
47 58 159 23 85 - - 68 158 80 78 106 -
48 74 154 31.2 90 - + 96 168 80 88 109.3 -
49 67 153 28.6 86 - + 73 148 90 58 109.3 I
50 72 163 27 78 - - 84 170 80 90 110 -
ISOLATED SYSTOLIC HYPERTENSION GROUP
Total no of patients 115 
MASTER CHART
Sl. 
No.
WT        
(kg)
HT        
(cm)
BMI   
(kg/m2)
WAIST  
(cm) JVP EDEMA
PULSE   
(per min)
SBP  
(mmHg)    
DBP  
(mmHg) 
PULSE 
PRESSURE 
(mmHg) 
MAP 
(mmHg) FUNDUS
51 50 158 20 92 - - 82 150 90 60 110 -
52 82 172 27.7 80 - - 80 180 90 90 120 -
53 66 158 26.4 87 - - 76 152 80 72 104 -
54 68 154 28.6 79 - - 86 200 82 118 119.3 -
55 51 149 23 86 - + 76 198 72 126 114 -
56 50 159 19.7 80 - - 78 164 90 74 114.6 -
57 63 149 28.9 87 - - 80 150 80 70 103.3 -
58 66 154 27.8 82 - - 80 170 80 90 110 -
59 67 150 29.7 84 - - 82 176 70 106 105.3 -
60 53 154 22.3 89 - - 78 180 90 90 120 -
61 66 151 28.9 86 - - 90 148 74 74 98.6 -
62 50 162 19 84 - - 70 168 78 90 108 -
63 49 153 21 82 - - 86 170 80 90 110 -
64 54 161 20.8 87 - + 74 152 84 60 106.6 -
65 71 160 27.7 80 - - 76 180 70 110 106.6 -
66 55 158 22 79 - - 82 158 90 68 112.6 -
67 80 170 27.6 88 - - 90 190 70 120 110 -
68 66 152 28.5 82 - - 88 144 80 64 101.3 -
69 53 155 22 88 - - 82 192 70 122 110.6 -
70 66 150 29.3 90 - - 70 180 86 94 117.3 -
71 50 158 20 86 - - 78 172 90 82 117.3 -
72 74 163 27.8 81 - - 75 156 80 76 105.3 -
73 65 153 27.7 87 + - 82 158 70 88 99.3 -
74 50 152 21.6 78 - - 96 200 82 118 121.3 -
75 68 160 26.5 89 - - 80 150 90 60 110 I
Total no of patients 115 
HT        
(cm)
BMI   
(kg/m2)
WAIST  
(cm) JVP
MASTER CHART
ISOLATED SYSTOLIC HYPERTENSION GROUP
Sl. 
No.
WT        
(kg) EDEMA
PULSE   
(per min)
SBP  
(mmHg)    
DBP  
(mmHg) 
PULSE 
PRESSURE 
(mmHg) 
MAP 
(mmHg) FUNDUS
76 53 151 23.2 92 - - 74 192 86 106 121.3 -
77 69 153 29.4 82 - + 80 170 80 90 110 -
78 59 162 22.4 83 - - 76 160 76 84 104 -
79 67 152 28.9 91 - + 94 180 90 90 120 -
80 84 173 28 85 - - 82 156 90 66 112 -
81 55 154 23.1 81 - - 87 152 70 82 97.3 -
82 54 150 24 78 - - 72 172 72 100 105.3 -
83 55 153 23.4 86 - - 84 164 70 94 101.3 -
84 65 151 28.5 94 - - 90 148 80 68 102.6 -
85 56 157 22.7 85 - - 88 190 74 116 112.6 -
86 63 155 26.2 88 + - 82 152 80 72 104 -
87 64 160 25 96 - - 76 180 80 100 113.3 -
88 61 153 26 79 - - 74 176 76 100 109.3 I
89 62 153 26.8 90 - - 86 160 80 80 106.6 -
90 70 161 27 89 - - 80 190 70 120 110 -
91 63 152 27.2 92 - - 90 182 80 102 114 -
92 64 163 24 82 - - 73 176 72 104 106.6 I
93 70 160 27.3 90 - + 86 150 88 62 108.6 -
94 72 162 27.4 87 - - 72 200 80 120 120 -
95 74 167 26.5 83 - - 96 190 90 100 123.3 -
96 60 155 25 98 - - 78 158 70 88 99.3 -
97 70 162 26.6 84 - - 92 186 70 116 108.6 -
98 74 164 27.5 80 - - 82 160 90 70 113.3 -
99 56 158 22.4 88 - - 80 170 76 94 107.3 -
100 56 156 23 94 - - 90 156 80 76 105.3 -
ISOLATED SYSTOLIC HYPERTENSION GROUP
Total no of patients 115 
MASTER CHART
Sl. 
No.
WT        
(kg)
HT        
(cm)
BMI   
(kg/m2)
WAIST  
(cm) JVP EDEMA
PULSE   
(per min)
SBP  
(mmHg)    
DBP  
(mmHg) 
PULSE 
PRESSURE 
(mmHg) 
MAP 
(mmHg) FUNDUS
101 72 158 28.8 88 - - 82 164 72 92 102.6 -
102 80 160 31.5 83 - - 90 156 84 72 108 -
103 54 150 24 92 - - 94 190 82 108 118 I
104 64 155 26.6 90 - - 96 150 72 78 98 -
105 55 153 23.4 87 - + 80 168 88 80 114.6 -
106 85 163 32 82 - - 96 160 90 70 113.3 II
107 53 154 22.3 102 - - 88 180 84 96 116 -
108 68 160 26.5 79 - - 90 160 80 80 106.6 -
109 73 156 30 83 - - 80 170 88 82 115.3 I
110 58 159 23 96 - - 84 158 74 84 102 -
111 64 151 28 78 - - 92 174 80 94 111.3 -
112 60 158 24 90 - - 88 152 74 78 100 -
113 81 162 31 80 - - 82 162 90 72 114 -
114 75 165 27.5 88 - - 98 200 84 116 122.6 -
115 70 156 28.7 80 - - 84 182 76 106 111.3 -
Total no of patients 115 
HT        
(cm)
BMI   
(kg/m2)
WAIST  
(cm) JVP EDEMA
PULSE   
(per min)
MASTER CHART
ISOLATED SYSTOLIC HYPERTENSION GROUP
Sl. 
No.
WT        
(kg)
SBP  
(mmHg)    
DBP  
(mmHg) 
PULSE 
PRESSURE 
(mmHg) 
MAP 
(mmHg) FUNDUS
1 67 150 29.7 85 - - 82 170 98 72 122 -
2 69 153 29.4 87 - - 84 156 92 64 113.3 -
3 48 159 19 79 - - 64 188 110 78 136 -
4 50.5 155 21 90 - - 78 220 100 120 140 I
5 66 154 27.8 92 - - 82 176 100 76 125.3 -
6 60 158 24 88 - + 84 172 96 76 121.3 -
7 63 149 28.9 80 - - 73 170 100 70 123.3 -
8 68 156 27.9 83 - - 90 190 94 96 126.0 -
9 82 172 27.7 86.5 + + 86 160 94 66 116 II
10 47 160 18.3 78 - - 88 180 120 60 140 -
11 63 162 24 84 - - 78 174 110 64 131.3 -
12 56 156 23 88 - - 90 184 104 80 130.6 -
13 68 166 24.6 82 - - 100 186 106 80 132.6 -
14 47 146 22 80 - + 86 152 114 38 126.6 -
15 58 159 23 87 - - 88 188 100 88 129.3 I
16 53 152 23 84.5 - - 92 160 110 50 126.6 -
17 59 157 23.9 90.5 + + 94 170 100 70 123.3 -
18 67 154 28.2 79 - - 90 150 106 44 120.6 -
19 52 147 24 86.5 - - 92 176 110 66 132 -
20 67 152 28.9 81 - - 82 180 110 70 133.3 I
21 53 155 22 84 - - 84 200 100 100 133.3 -
22 80 171 27.3 88 - - 86 164 120 44 134.6 -
23 53 154 22.3 82 - - 85 190 104 86 132.6 -
24 67 153 28.6 87 - - 78 186 106 80 132.6 -
25 66 154 27.8 88 - - 88 200 110 90 140 -
MASTER CHART
ESSENTIAL HYPERTENSION GROUP
Total no of patients 50
Sl. 
No.
WT        
(kg)
HT        
(cm)
BMI      
(kg/m2)
WAIST    
(cm) JVP EDEMA
PULSE    
(per min)
SBP     
(mmHg) 
DBP     
(mmHg) 
PULSE 
PRESSURE 
(mmHg) 
MAP     
(mmHg) FUNDUS
26 53 154 22.3 78 - - 76 150 104 46 119.3 -
27 66 153 28.1 86 - - 80 178 92 86 120.6 -
28 74 163 27.8 79 - - 72 182 102 80 128.6 -
29 67 152 28.9 83 - - 78 210 104 106 139.3 I
30 50 159 19.7 88 - - 74 170 106 64 127.3 -
31 67 152 28.9 80 - - 82 152 100 52 117.3 -
32 70 162 26.6 91 - - 85 170 100 70 123.3 -
33 59 162 22.4 90 - - 84 180 94 86 122.6 -
34 56 156 23 81 - - 90 200 98 102 132 I
35 70 161 27 80 - - 82 184 106 78 132 -
36 50 152 21.6 87 - - 88 180 120 60 140 -
37 55 162 21 84 - - 90 172 114 58 133.3 -
38 64 163 24 89 - - 84 160 108 52 125.3 -
39 48 152 20.7 82 - - 92 184 100 84 128 -
40 54 150 24 84 - - 86 180 94 86 122.6 -
41 50 158 20 82.5 - - 80 188 110 78 136 II
42 60 158 24 85 - - 90 148 96 52 113.3 -
43 55 158 22 87 - - 88 182 110 72 134 -
44 74 164 27.5 83 - - 85 170 94 76 119.3 -
45 56 157 22.7 88 - - 82 160 100 60 120 -
46 67 152 28.9 86.5 - - 78 186 98 88 137.3 -
47 68 166 24.6 82 - - 84 176 92 84 120 I
48 66 151 29 87 - - 73 158 110 48 126 -
49 60 160 23.4 89 - - 86 190 100 90 130 -
50 70 156 28.7 80 - - 90 180 120 60 140 -
Total no of patients 50
MASTER CHART
ESSENTIAL HYPERTENSION GROUP
Sl. 
No.
WT        
(kg)
HT        
(cm)
BMI      
(kg/m2)
WAIST    
(cm) JVP EDEMA
PULSE    
(per min)
SBP     
(mmHg) 
DBP     
(mmHg) 
PULSE 
PRESSURE 
(mmHg) 
MAP     
(mmHg) FUNDUS

1 11 15 102 28 0.8 140 3.5 134 109 52 22 166 9.6 2.3 + + LVH -
2 9 11 91 26 1.4 143 3.4 242 200 54 14 112 8.6 3.6 - - - -
3 10.4 50 125 22 0.5 134 3.7 200 74 36 26 220 9.3 3.3 - + - -
4 10.2 7 112 20 2 140 4.7 206 158 55 32 152 9.8 4.2 - - - -
5 8.2 16 118 26 0.6 137 3.3 194 64 48 33 134 10 4 - + LVH -
6 10.7 41 240 50 1.5 139 5.0 236 188 56 27 142 10.2 2.6 - + LVH -
7 12 14 132 28 0.9 142 3.9 144 143 48 25 182 9.6 5 - - - -
8 12.7 12 129 24 0.4 132 3.8 294 68 35 23 138 8.3 7.2 - + - -
9 11.8 10 234 25 0.7 131 3.8 211 75 42 20 137 9.2 3.3 ++ + - K
10 9.4 20 81 16 1.3 141 4.8 128 111 46 32 83 9.6 3.6 - - - -
11 10.5 6 119 18 1.1 137 4.7 310 172 36 36 203 9.3 2.6 - - HK -
12 10.8 37 270 64 1.5 134 3.7 243 121 50 29 56 9.2 3.4 - + LVH -
13 11.9 14 116 38 1.4 135 5.0 207 76 37 21 120 9.6 4 - - - -
14 8.6 12 90 40 1.1 147 3.6 263 182 58 41 138 9.7 5.2 - - - CL
15 11.2 19 214 25 + 141 3.0 222 122 50 16 48 10.8 3.8 + - LVH -
16 8.8 12 103 23 0.8 135 4.5 128 232 66 25 136 9.3 2.6 - - - -
17 11.6 25 144 22 0.5 138 4.8 152 98 42 44 200 9.8 2.4 - - - -
18 9.2 13 302 28 1.3 135 4.1 280 82 49 37 55 10.7 4.2 - - HK -
19 11.4 20 111 24 0.7 144 5.0 224 168 39 15 96 9.7 3.3 - - - -
20 10.9 15 292 27 1.2 142 4.6 162 60 53 23 88 9.6 3.8 - - - -
21 11.5 14 93 24 1.3 141 3.1 156 117 42 40 82 9.3 2.6 - - - -
22 9.2 46 101 23 0.9 130 3.9 300 108 48 37 90 8.4 3.2 - - - -
23 12.5 13 286 31 0.4 143 3.2 210 111 35 15 172 9.7 3.4 - - LVH -
24 12.0 11 113 28 1.1 131 4.4 160 200 40 41 144 8.8 2.8 - - - -
25 9.0 40 105 21 0.7 144 4.1 188 112 51 31 66 9.6 4.4 + + - -
MASTER CHART
ISOLATED SYSTOLIC HYPERTENSION GROUP
Total no of patients 115 
LDL 
(mg/dl)
SE  
CALCI
UM 
(mg/dl)
SE     
URIC  
ACID 
(mg/dl)
URINE  
ALB ECG ECHO
USG   
ABD
TOTAL 
CHOLES 
(mg/dl)
TGL 
(mg/dl)
HDL 
(mg/dl)
VLDL 
(mg/dl)
UREA 
(mg/dl)
CREAT 
ININE 
(mg/dl)
NA+ 
(Meq/L)
K+ 
(Meq/L)
Sl. 
No.
HB   
(gm)
ESR 
(mm)
SUGAR 
(mg/dl)
26 11.7 16 80 50 1.3 140 4.8 230 152 58 12 162 9.1 5.0 - - - -
27 8.0 13 243 30 0.4 137 5.0 143 177 50 33 57 9.8 2.4 - + - -
28 10.6 10 100 22 0.5 132 3.1 206 110 34 29 136 8.9 2.6 - + - -
29 8.8 16 89 26 0.8 145 5.0 307 210 57 37 140 9.2 8.8 ++ + - -
30 10.2 32 310 30 1.4 133 5.7 236 124 50 27 152 9.0 3.2 - - HK -
31 11.3 12 111 38 1.0 131 3.3 286 113 45 23 170 9.3 3.6 - - - -
32 10.8 9 262 40 1.8 144 3.2 138 68 44 19 144 8.3 4.2 - + - -
33 10.5 14 117 27 1.2 134 4.1 210 165 62 20 114 9.4 2.8 - - LVH K
34 8.7 18 82 22 0.5 136 4.6 272 129 42 22 122 10.7 5.0 + - - -
35 10.7 26 104 25 1.4 143 4.0 224 89 37 25 168 9.7 6.0 - + - -
36 10.3 11 306 20 1.2 132 4.2 214 220 46 21 68 9.6 3.3 - + - -
37 7.6 13 92 62 0.6 144 3.3 192 158 40 44 53 9.8 5.7 - - - K
38 12.6 10 274 23 1.2 133 4.2 256 172 45 20 180 9.0 2.5 + + LVH -
39 9.8 17 83 29 1.5 139 3.3 169 147 39 26 166 10.8 3.3 - + LVH -
40 11.4 15 114 31 0.4 142 4.9 134 146 41 30 188 9.4 3.5 - - - -
41 9.8 10 286 48 1.5 144 3.6 136 116 36 22 120 8.6 3.2 - - - -
42 11.7 32 88 33 0.9 141 4.2 312 69 52 31 126 9.4 2.6 - + LVH -
43 10.5 18 300 21 1.0 133 4.9 132 180 42 43 130 9.6 2.2 - + - K
44 10.8 17 95 19 1.1 135 5.0 272 122 39 27 192 9.4 2.8 + + - -
45 8.6 13 110 35 0.6 141 4.8 207 144 54 41 131 9.5 3.2 - + - -
46 12.4 11 84 40 0.9 143 3.4 128 142 50 43 55 10.6 3.6 - - LVH -
47 10.9 30 224 34 1.0 138 4.0 148 112 37 13 168 9.3 3.6 - + - -
48 9.2 7 120 37 0.6 140 3.5 281 200 42 28 136 8.4 3.5 - + LVH -
49 10.5 18 99 20 1.0 136 3.8 229 119 50 30 200 10.2 4.6 - - - -
50 10.2 40 236 32 1.1 134 4.6 173 100 44 26 100 10.0 5.2 ++ - - -
ISOLATED SYSTOLIC HYPERTENSION GROUP
Total no of patients 115 
MASTER CHART
Sl. 
No.
HB   
(gm)
ESR 
(mm)
SUGAR 
(mg/dl)
UREA 
(mg/dl)
CREAT 
ININE 
(mg/dl)
NA+ 
(Meq/L)
K+ 
(Meq/L)
TOTAL 
CHOLES 
(mg/dl)
TGL 
(mg/dl)
HDL 
(mg/dl)
VLDL 
(mg/dl)
LDL 
(mg/dl)
SE  
CALCI 
UM  
(mg/dl)
SE     
URIC  
ACID 
(mg/dl)
URINE  
ALB ECG ECHO
USG   
ABD
51 8.0 16 94 27 1.5 142 4.7 212 188 34 15 150 10.2 6.8 - + HK -
52 11.5 8 106 20 0.7 138 3.5 237 152 41 25 48 9.6 3.3 - + - -
53 8.4 14 244 18 0.8 132 3.6 164 118 43 16 182 9.4 3.5 - - - -
54 12.8 25 115 32 0.6 137 3.9 214 166 58 21 133 8.3 2.8 - + - FL
55 11.5 10 286 28 0.7 135 4.3 265 84 56 28 46 9.3 2.6 + - LVH -
56 10.3 17 87 29 0.9 133 4.1 232 178 64 25 166 10.6 8.4 - - - -
57 9.4 8 123 36 1.0 139 4.6 171 152 48 38 150 9.6 3.0 - - - -
58 10.7 16 212 21 1.2 144 4.5 226 88 51 18 42 9.8 3.3 - + HK -
59 7.4 92 71 112 3.0 138 3.4 186 192 35 41 160 9.4 4.4 - + - K
60 10.6 9 118 33 0.9 130 3.8 270 150 52 33 148 9.0 5.2 - - - -
61 11.2 19 110 36 0.8 130 4.6 307 89 49 26 152 9.3 2.3 - - LVH -
62 10.4 7 242 19 0.5 137 3.7 181 97 43 30 88 9.6 2.6 - + - -
63 9.6 9 128 35 0.9 130 5.0 298 98 39 16 212 8.6 3.5 - + - -
64 11.7 20 111 19 0.7 135 3.2 211 210 53 28 101 9.4 11.0 + + - -
65 12.3 9 210 46 0.9 144 4.5 220 146 59 24 144 9.1 3.6 - - HK K
66 11.0 26 180 29 1.3 138 4.4 190 96 46 24 67 9.8 3.0 - - LVH -
67 9.2 9 162 35 1.2 136 3.6 224 176 34 30 200 9.0 2.8 ++ - - -
68 10.2 19 306 18 0.7 137 4.8 188 150 47 17 48 10.7 2.2 - - - -
69 11.6 5 97 39 0.4 135 3.1 312 148 51 26 140 9.6 5.0 - + LVH -
70 8.2 60 290 17 1.1 134 3.4 211 168 45 42 42 9.6 2.5 - + - -
71 10.4 18 80 56 1.4 131 4.4 148 88 34 28 210 8.8 3.6 - - - K
72 11.5 6 146 34 0.8 139 5.7 220 117 50 46 58 10.2 4.2 - - - -
73 9.0 18 232 18 1.5 141 4.5 296 182 52 43 186 10.0 4.0 + + HK -
74 10.3 8 119 34 1.2 137 3.1 230 110 37 20 62 9.2 5.2 + + - FL
75 8.3 32 124 16 0.6 138 4.7 164 149 49 27 142 9.0 2.0 - + - -
Total no of patients 115 
MASTER CHART
ISOLATED SYSTOLIC HYPERTENSION GROUP
Sl. 
No.
HB   
(gm)
ESR 
(mm)
SUGAR 
(mg/dl)
UREA 
(mg/dl)
CREAT 
ININE 
(mg/dl)
NA+ 
(Meq/L)
K+ 
(Meq/L)
TOTAL 
CHOLES 
(mg/dl)
TGL 
(mg/dl)
HDL 
(mg/dl)
VLDL 
(mg/dl)
LDL 
(mg/dl)
SE  
CALCI
UM 
(mg/dl)
SE     
URIC  
ACID 
(mg/dl)
URINE  
ALB ECG ECHO
USG   
ABD
76 10.6 7 300 36 1.3 143 4.3 214 176 45 41 88 10.2 2.5 - - LVH -
77 10.8 40 126 38 0.8 136 3.8 284 90 44 16 196 10.6 2.6 - + - -
78 9.1 8 256 30 1.0 144 4.7 218 112 36 37 158 9.4 3.2 - - - -
79 10.5 6 109 37 1.1 132 4.3 182 180 52 45 201 9.2 3.8 - + - -
80 11.3 20 122 33 0.8 140 3.3 300 114 56 33 132 9.6 4.0 - + - -
81 9.1 12 118 38 1.1 130 5.0 307 126 48 41 138 10.0 2.2 - + - -
82 11.9 5 240 16 0.6 142 3.6 224 116 35 25 73 9.3 2.8 - + - -
83 10.7 30 152 32 0.7 137 4.1 126 100 54 33 192 9.6 3.2 + - - -
84 8.2 6 200 29 1.3 133 4.4 138 112 56 37 142 9.8 3.0 - - - -
85 11.4 5 276 39 0.4 142 4.9 208 200 60 23 148 9.4 4.2 - - LVH -
86 10.3 15 108 17 0.8 133 4.5 162 96 38 13 156 9.8 3.5 - + - K
87 12.2 25 86 21 1.4 140 3.9 223 140 47 24 80 9.0 2.6 - + - -
88 11.4 20 98 40 0.6 131 3.8 260 186 45 38 186 9.2 3.3 + + - -
89 8.9 38 140 23 0.5 142 3.3 238 156 36 32 46 9.0 3.7 - - - -
90 11.6 6 312 17 1.2 144 5.0 194 88 41 30 57 9.8 10.6 - - HK FL
91 13 44 157 19 0.9 131 3.5 219 164 46 28 62 8.3 4.3 - + LVH -
92 11.6 17 96 37 1.4 139 5.5 132 89 55 44 188 9.6 4.0 - - - -
93 11.8 5 226 40 0.4 138 4.1 152 192 57 28 66 9.4 5.2 - + - -
94 10.5 19 74 58 1.5 134 3.5 301 117 38 16 133 9.3 2.8 - + - -
95 8.1 11 212 31 1.0 132 3.2 227 178 44 23 80 10.8 2.5 ++ - LVH -
96 11.0 13 85 17 0.5 141 4.8 181 140 47 38 220 9.2 2.7 - + - -
97 12.0 5 107 38 1.3 132 4.0 230 118 60 32 92 9.0 2.3 - + HK -
98 8.6 8 192 39 1.0 143 3.7 272 93 38 40 172 9.1 3.6 - - - -
99 10.2 7 232 16 0.4 134 5.0 201 132 52 12 110 9.6 2.6 - - LVH FL
100 9.3 20 76 79 1.5 136 4.2 129 98 48 46 168 9.8 2.4 - + - FL
ISOLATED SYSTOLIC HYPERTENSION GROUP
Total no of patients 115 
MASTER CHART
Sl. 
No.
HB   
(gm)
ESR 
(mm)
SUGAR 
(mg/dl)
UREA 
(mg/dl)
CREAT 
ININE 
(mg/dl)
NA+ 
(Meq/L)
K+ 
(Meq/L)
TOTAL 
CHOLES 
(mg/dl)
TGL 
(mg/dl)
HDL 
(mg/dl)
VLDL 
(mg/dl)
LDL 
(mg/dl)
SE  
CALCI
UM 
(mg/dl)
SE     
URIC  
ACID 
(mg/dl)
URINE  
ALB ECG ECHO
USG   
ABD
101 11.2 13 150 30 0.9 136 3.5 310 202 55 16 165 9.6 3.4 - + - -
102 9.6 19 173 18 0.6 144 3.8 235 156 58 35 123 8.8 2.8 - - - -
103 12 20 250 33 0.8 142 3.6 288 207 46 38 203 9.2 4.4 ++ - - -
104 9.2 9 178 23 0.8 131 4.8 220 140 48 17 200 10 5 - + HK -
105 10.5 11 165 15 1.1 142 5 288 210 56 14 172 9 2.4 - - - K
106 11 15 120 40 0.7 135 5.3 301 120 58 16 135 8.6 2.8 ++ - - -
107 9 10 265 35 0.5 139 4.1 316 240 38 25 180 10.2 3.8 - - LVH -
108 11.5 20 128 17 + 136 4.7 216 122 36 33 142 9.4 5 - - - -
109 9.3 16 134 16 0.9 140 4.6 212 232 45 12 192 9.2 2.8 - - - -
110 11 19 126 21 0.5 138 5.2 242 110 33 44 188 8.3 2.5 - + - -
111 11.4 15 290 15 0.8 138 5.4 232 98 35 18 166 9.4 5.7 + - LVH K
112 10.4 8 130 18 0.5 143 5 280 225 44 22 172 9.1 2.3 - - - -
113 12 12 115 28 0.7 130 4.8 210 106 34 15 220 9.6 3.5 - - - -
114 9.2 10 300 33 0.8 136 4.6 268 216 40 18 170 9 2.6 - - - FL
115 10 14 116 38 0.6 142 5.2 228 238 36 20 200 9.4 5.2 - - HK -
Total no of patients 115 
MASTER CHART
ISOLATED SYSTOLIC HYPERTENSION GROUP
Sl. 
No.
HB   
(gm)
ESR 
(mm)
SUGAR 
(mg/dl)
UREA 
(mg/dl)
CREAT 
ININE 
(mg/dl)
NA+ 
(Meq/L)
K+ 
(Meq/L)
TOTAL 
CHOLES 
(mg/dl)
TGL 
(mg/dl)
HDL 
(mg/dl)
VLDL 
(mg/dl)
LDL 
(mg/dl)
SE  
CALCI
UM 
(mg/dl)
SE     
URIC  
ACID 
(mg/dl)
URINE  
ALB ECG ECHO
USG   
ABD
1 10.8 12 114 37 0.80 130 3.7 196 78 34 19 182 9.6 4.2 - - - -
2 12.4 14 220 22 0.40 137 5.0 186 120 62 44 144 10.0 3.8 + + - -
3 8.6 10 160 28 1.0 135 3.2 200 112 37 22 75 9.2 3.2 - - - -
4 9.2 30 142 40 1.1 144 4.5 222 200 42 30 176 9.3 2.4 + - LVH -
5 10.5 46 312 68 1.2 138 3.6 263 130 36 19 132 10.7 8.8 - + HK K
6 8 32 112 25 1.0 136 4.8 230 164 48 32 162 8.4 4.8 - - - -
7 11.5 9 78 39 0.8 135 3.4 192 108 46 15 200 8.6 2.3 + + - -
8 12.6 11 280 24 0.6 131 4.4 236 92 35 12 157 10.4 2.8 - - LVH -
9 8.4 16 88 21 0.5 134 5.7 240 225 43 24 64 9.3 4.2 - + - -
10 9.2 13 300 60 2.2 139 4.5 280 115 46 36 133 9.9 3.5 + - HK K
11 12.8 14 180 30 0.5 141 3.1 194 230 39 32 105 9.4 11.0 - - - -
12 7.6 09 310 38 0.8 137 4.7 224 110 44 15 142 8.8 5.8 + - HK -
13 9.4 11 112 27 1.2 143 4.3 284 136 36 19 198 10.0 2.6 - + - -
14 8.7 17 90 32 0.6 136 3.8 306 168 52 23 58 9.5 3.8 - + - -
15 10.6 10 280 112 3.6 138 4.3 198 102 45 26 168 9.4 5.6 + + LVH K
16 12.5 18 86 36 0.6 144 4.9 210 80 53 29 154 10.2 4.0 - - - -
17 12.5 15 320 19 0.9 132 3.5 188 100 45 43 52 10.8 2.8 - + - FL
18 10.7 32 104 23 1.1 141 4.1 258 96 38 18 102 9.8 4.2 + - - -
19 12.4 07 94 29 1.0 133 3.6 216 176 47 31 64 9.6 3.8 - + - -
20 9.8 17 275 33 1.2 136 4.5 230 82 46 13 134 9.6 10.6 - - LVH -
21 10.3 18 130 36 1.0 140 3.2 186 115 58 38 210 9.8 3.0 - + HK -
22 12.0 08 340 20 1.2 134 4.4 272 212 48 18 146 9.7 4.4 - - - -
23 11.2 40 142 26 1.1 138 5.0 228 102 38 14 78 9.8 2.8 ++ + HK -
24 12.5 25 160 31 0.8 142 3.2 296 116 46 18 133 10.0 3.0 - - - -
25 12.5 14 114 35 0.7 142 4.2 216 202 44 23 152 10.2 2.5 - + - -
Total no of patients 50
MASTER CHART
 ESSENTIAL HYPERTENSION GROUP
Sl. 
No.
HB   
(gm)
ESR   
(mm)
SUGAR 
(mg/dl)
UREA  
(mg/dl)
CREAT 
ININE  
(mg/dl)
NA+   
(Meq/L)
K+    
(Meq/L)
TOTAL 
CHOLES 
(mg/dl)
TGL   
(mg/dl)
HDL  
(mg/dl)
VLDL  
(mg/dl)
LDL   
(mg/dl)
SE  
CALCI
UM    
(mg/dl)
SE     
URIC  
ACID  
(mg/dl)
URINE  
ALB ECG ECHO
USG   
ABD
26 11.7 16 120 18 + 143 3.4 196 146 38 23 116 9.2 3.0 - - - -
27 10.3 13 170 24 + 130 3.7 188 196 53 42 120 9.6 5.2 - + - -
28 11.0 10 280 16 0.8 144 4.7 236 142 49 34 138 10.4 2.6 - - LVH -
29 9.4 15 124 27 0.5 137 5.0 312 122 44 13 98 9.4 4.8 - + HK -
30 8.2 32 162 30 0.9 132 3.5 192 178 36 25 182 9.1 4.0 ++ - - K
31 9.6 7 220 22 + 145 4.5 234 120 57 45 58 9.6 11.0 - - - -
32 12.8 12 152 56 + 131 3.3 220 150 56 27 210 10.3 3.2 - + - -
33 9.2 9 242 25 0.4 136 3.8 196 164 34 15 176 10.0 2.1 - + - -
34 13.0 26 126 18 0.6 144 3.6 230 68 52 16 102 9.9 3.5 - + - -
35 10.5 14 290 78 1.1 131 4.7 310 110 50 39 136 9.3 2.6 - - - K
36 11.5 18 320 17 1.2 133 3.0 216 148 37 17 124 9.4 2.8 - - - -
37 11.3 15 144 34 0.5 140 4.8 190 185 58 26 148 10.6 2.4 - + HK -
38 10.5 11 230 31 0.8 142 4.1 234 185 38 14 166 8.6 2.2 - - - -
39 8.6 50 400 20 1.1 131 5.0 236 104 57 12 210 10.8 3.0 - - - FL
40 11.4 13 160 19 0.9 139 4.8 186 190 55 33 112 9.8 4.2 + - - -
41 8.1 10 312 72 1.2 147 5.0 216 106 56 44 140 10.2 4.8 - + - K
42 13 17 140 32 0.6 135 4.6 188 1722 51 12 106 9.8 2.3 - + LVH -
43 9.3 14 146 21 0.8 138 3.1 288 92 33 41 45 9.6 4.0 - - - K
44 12.0 11 84 26 1.1 136 3.3 220 130 36 28 150 10.8 5.3 - - HK -
45 10.2 16 288 28 0.7 145 5.7 190 196 55 17 190 8.6 5.4 ++ + - -
46 11.0 30 222 32 0.7 142 4.1 200 98 54 35 175 10.1 4.8 - + - FL
47 9.0 14 98 23 0.8 132 4.0 300 78 35 16 94 10.8 2.5 - - - -
48 10.2 20 122 35 1.2 140 4.6 194 84 60 40 156 10.3 5.6 - + - -
49 10.6 12 136 29 1.8 133 3.3 316 130 34 22 88 10.6 3.5 - - - -
50 9.2 25 214 33 0.8 138 4.2 218 96 37 14 182 9.8 6.6 - + - -
Total no of patients 50
MASTER CHART
ESSENTIAL HYPERTENSION GROUP
Sl. 
No.
HB   
(gm)
ESR   
(mm)
SUGAR 
(mg/dl)
UREA  
(mg/dl)
CREAT 
ININE  
(mg/dl)
NA+   
(Meq/L)
K+    
(Meq/L)
TOTAL 
CHOLES 
(mg/dl)
TGL   
(mg/dl)
HDL  
(mg/dl)
VLDL  
(mg/dl)
LDL   
(mg/dl)
SE  
CALCI
UM    
(mg/dl)
SE     
URIC  
ACID  
(mg/dl)
URINE  
ALB ECG ECHO
USG   
ABD

